A PHASE 1, OPEN-LABEL, 3-TREATMENT, 6-SEQUENCE, 3-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF-07321332/RITONAVIR AND RITONAVIR ON THE PHARMACOKINETICS OF DABIGATRAN IN HEALTHY PARTICIPANTS
Phase: PHASE1
Conditions: Healthy Participants
Sponsor: Pfizer

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 1
A PHASE 1, OPEN-LABEL, 3-TREATMENT, 6-SEQUENCE, 3-PERIOD 
CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF-07321332/RITONAVIR
AND RITONAVIR ON THE PHARMACOKINETICS OF DABIGATRAN IN 
HEALTHY PARTICIPANTS
Study Intervention Number:
PF-07321332
Study Intervention Name:
N/A
US IND Number:
153517
EudraCT Number:
2021-003590-62
ClinicalTrials.gov ID: 
N/A
Protocol Number:
C4671012
Phase:
1
Brief Title: A Phase 1 Study to Estimate the Effect of PF-07321332/Ritonavir and 
Ritonavir on the PK of Dabigatran in Healthy Participants
This document and accompanying materials contain confidential information belonging to Pfizer. Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by applicable law) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 2
Document History
Document
Version Date
Original protocol
03 August 2021

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 3
TABLE OF CONTENTS
LIST OF TABLES.....................................................................................................................8
1. PROTOCOL SUMMARY.....................................................................................................9
1.1. Synopsis ....................................................................................................................9
1.2. Schema ....................................................................................................................15
1.3. Schedule of Activities .............................................................................................16
2. INTRODUCTION ...............................................................................................................25
2.1. Study Rationale .......................................................................................................25
2.2. Background .............................................................................................................26
2.2.1. Nonclinical Pharmacology..........................................................................26
2.2.2. Nonclinical Pharmacokinetics and Metabolism .........................................26
2.2.3. Nonclinical Safety ......................................................................................27
2.2.4. Clinical Overview.......................................................................................27
2.2.4.1. Safety Overview........................................................................28
2.2.4.2. Summary of PF-07321332 Pharmacokinetics in Human..........28
2.3. Benefit/Risk Assessment.........................................................................................29
2.3.1. Risk Assessment.........................................................................................30
2.3.2. Benefit Assessment.....................................................................................33
2.3.3. Overall Benefit/Risk Conclusion................................................................33
3. OBJECTIVES AND ENDPOINTS.....................................................................................33
4. STUDY DESIGN.................................................................................................................33
4.1. Overall Design.........................................................................................................33
4.2. Scientific Rationale for Study Design.....................................................................35
4.2.1. Choice of Contraception/Barrier Requirements .........................................37
4.3. Justification for Dose ..............................................................................................37
4.4. End of Study Definition ..........................................................................................37
5. STUDY POPULATION......................................................................................................37
5.1. Inclusion Criteria.....................................................................................................38
5.2. Exclusion Criteria....................................................................................................38
5.3. Lifestyle Considerations..........................................................................................42
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 4
5.3.1. Vaccine and Exposure to Infections Guidelines.........................................42
5.3.2. Meals and Dietary Restrictions...................................................................42
5.3.3. Caffeine, Alcohol, and Tobacco .................................................................43
5.3.4. Activity .......................................................................................................43
5.3.5. Contraception..............................................................................................43
5.4. Screen Failures ........................................................................................................44
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY.................................44
6.1. Study Intervention(s) Administered........................................................................44
6.1.1. Administration............................................................................................44
6.2. Preparation, Handling, Storage, and Accountability...............................................45
6.2.1. Preparation and Dispensing........................................................................46
6.3. Measures to Minimize Bias: Randomization and Blinding.....................................46
6.3.1. Allocation to Study Intervention ................................................................46
6.4. Study Intervention Compliance...............................................................................46
6.5. Dose Modification...................................................................................................47
6.6. Continued Access to Study Intervention After the End of the Study......................47
6.7. Treatment of Overdose............................................................................................47
6.8. Concomitant Therapy..............................................................................................47
6.8.1. Rescue Medicine.........................................................................................48
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL...........................................................................48
7.1. Discontinuation of Study Intervention ....................................................................48
7.1.1. ECG Changes..............................................................................................49
7.1.2. Potential Cases of Acute Kidney Injury .....................................................49
7.1.3. Liver Injury.................................................................................................50
7.2. Participant Discontinuation/Withdrawal From the Study.......................................50
7.2.1. Withdrawal of Consent...............................................................................50
7.3. Lost to Follow-Up ...................................................................................................51
8. STUDY ASSESSMENTS AND PROCEDURES...............................................................51
8.1. Efficacy Assessments..............................................................................................52
8.2. Safety Assessments .................................................................................................52
8.2.1. Physical Examinations................................................................................53

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 5
8.2.2. Vital Signs ..................................................................................................53
8.2.2.1. Respiratory Rate........................................................................53
8.2.2.2. Temperature ..............................................................................54
8.2.3. Electrocardiograms.....................................................................................54
8.2.4. Clinical Safety Laboratory Assessments ....................................................55
8.2.5. COVID-19 Specific Assessments...............................................................55
8.2.6. Pregnancy Testing ......................................................................................55
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................56
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......56
8.3.1.1. Reporting SAEs to Pfizer Safety...............................................57
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF...................57
8.3.2. Method of Detecting AEs and SAEs ..........................................................57
8.3.3. Follow-up of AEs and SAEs.......................................................................58
8.3.4. Regulatory Reporting Requirements for SAEs...........................................58
8.3.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure.....................................................58
8.3.5.1. Exposure During Pregnancy......................................................59
8.3.5.2. Exposure During Breastfeeding ................................................60
8.3.5.3. Occupational Exposure .............................................................61
8.3.6. Cardiovascular and Death Events...............................................................61
8.3.7. Disease Related-Events and/or Disease Related- Outcomes Not 
Qualifying as AEs or SAEs..............................................................................61
8.3.8. Adverse Events of Special Interest.............................................................61
8.3.8.1. Lack of Efficacy........................................................................61
8.3.9. Medical Device Deficiencies......................................................................61
8.3.10. Medication Errors.....................................................................................61
8.4. Pharmacokinetics ....................................................................................................62
8.4.1. Plasma for Analysis of PF-07321332, Ritonavir, and Dabigatran .............62
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 6
8.7. Immunogenicity Assessments.................................................................................64
8.8. Health Economics ...................................................................................................64
9. STATISTICAL CONSIDERATIONS ................................................................................64
9.1. Statistical Hypotheses .............................................................................................64
9.2. Analysis Sets ...........................................................................................................64
9.3. Statistical Analyses .................................................................................................65
9.3.1. Pharmacokinetic Analyses..........................................................................65
9.3.1.1. Derivation of Pharmacokinetic Parameters Prior to 
Analysis .............................................................................................65
9.3.2. Statistical Methods for PK Data .................................................................66
9.3.3. Other Safety Analyses ................................................................................67
9.4. Interim Analyses .....................................................................................................67
9.5. Sample Size Determination.....................................................................................67
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS..........................................................................................................69
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations...............69
10.1.1. Regulatory and Ethical Considerations ....................................................69
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................69
10.1.2. Informed Consent Process ........................................................................70
10.1.3. Data Protection .........................................................................................71
10.1.4. Committees Structure ...............................................................................71
10.1.4.1. Data Monitoring Committee ...................................................71
10.1.5. Dissemination of Clinical Study Data ......................................................71
10.1.6. Data Quality Assurance ............................................................................72
10.1.7. Source Documents....................................................................................74
10.1.8. Study and Site Start and Closure ..............................................................74
10.1.9. Publication Policy.....................................................................................75
CCI
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 7
10.1.10. Sponsor’s Qualified Medical Personnel .................................................76
10.2. Appendix 2: Clinical Laboratory Tests .................................................................77
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................78
10.3.1. Definition of AE .......................................................................................78
10.3.2. Definition of an SAE ................................................................................79
10.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs During 
the Active Collection Period............................................................................80
10.3.4. Reporting of SAEs....................................................................................84
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................85
10.4.1. Male Participant Reproductive Inclusion Criteria....................................85
10.4.2. Female Participant Reproductive Inclusion Criteria.................................85
10.4.3. Woman of Childbearing Potential ............................................................86
10.4.4. Contraception Methods.............................................................................87
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments .......90
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................92
10.8. Appendix 8: Prohibited and Precautionary Concomitant Medications That 
May Result in DDI ....................................................................................................94
10.9. Appendix 9: Abbreviations ...................................................................................97
11. REFERENCES ................................................................................................................101
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 8
LIST OF TABLES
Table 1.
Plasma PK Parameters..............................................................................65
Table 2.
Protocol-Required Safety Laboratory Assessments .................................77

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 9
1. PROTOCOL SUMMARY 
1.1. Synopsis 
Brief Title: A Phase 1 Study to Estimate the Effect of PF-07321332/Ritonavir and 
Ritonavir on the PK of Dabigatran in Healthy Participants
Rationale
PF-07321332 is a potent and selective inhibitor of the SARS-CoV-2 3CL protease that is 
currently being developed as an oral treatment of COVID-19. Ritonavir is a strong CYP3A4 
inhibitor being used to inhibit the metabolism of PF-07321332 in order to increase plasma 
concentrations of PF-07321332 to values that are anticipated to be efficacious. 
In vitro and in vivo metabolite profiling suggests that the primary clearance mechanism for 
PF-07321332 is CYP3A4 mediated oxidation. In a reaction phenotyping study using human 
liver microsomes in the presence of selective CYP inhibitors, CYP3A4 was predicted to be 
the major contributor (fm = 0.99) to the in vitro oxidative metabolism of PF-07321332. As 
such, in the FIH study, C4671001, the CYP3A4 inhibitor ritonavir was used to enhance the 
exposure of PF-07321332 in order to achieve plasma levels that are anticipated to be 
efficacious. Preliminary PK data following multiple oral administrations of 
PF‑07321332/ritonavir at doses of 75/100 mg, 250/100 mg, and 500/100 mg q12h suggest 
that the renal pathway may also play a significant role in PF-07321332 excretion when 
co-administered with ritonavir, with approximately 32.5% (PF‑07321332/ritonavir 
500/100 mg) to 64.6% (PF‑07321332/ritonavir 75/100 mg) of the drug excreted unchanged 
in urine across doses at steady-state, and renal clearance ranging between 3.5 to 4.4 L/h 
across doses. Ritonavir is extensively metabolized, primarily by CYP3A4.1
The DDI potential of PF-07321332 was further evaluated using a static mechanistic model
using the projected Cmax for reversible inhibition or Cav time-dependent inhibition in plasma,
intestinal lumen, enterocytes, liver, and portal inlet (incorporating kp,uu and ka). Based on this
model, PF-07321332 has minimal risk to inhibit CYPs other than 3A4, UGTs and transport 
proteins; however, the potential remains to reversibly and time-dependently inhibit CYP3A4 
and inhibit P-gp in humans at the proposed therapeutic dose. 
Dabigatran etexilate (herein referred to as dabigatran) is a sensitive probe substrate of the 
efflux transporter P-gp that experiences a ≥2 fold increase in exposure upon coadministration 
with P-gp inhibitors verapamil or quinidine.2 Additionally, dabigatran is primarily renally 
eliminated by glomerular filtration (approximately 80%).2
Ritonavir is classified as a P-gp inhibitor. Although limited clinical data exist on drug-drug 
interactions with ritonavir and P-gp probe substrates like dabigatran, results from a study 
assessing the concomitant administration of dabigatran etexilate and ritonavir did not result 
in statistically significant changes in any of the PK parameters of dabigatran or changes in 
thrombin time measures as compared to dabigatran administered alone. However, there was 
statistically significant and similar decreases in the dabigatran AUC and Cmax when 
dabigatran and ritonavir were administered separately by 2 hours compared to values 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 10
obtained when dabigatran was administered alone, suggesting there may be the potential of 
ritonavir to induce P-gp. Even though dabigatran is primarily renally eliminated, results
suggested that whether dabigatran and ritonavir were administered simultaneously or 
separated by 2 hours, there was no change in dabigatran t½ or Kel compared to dabigatran 
administered alone.2
Based on available data to date, it is possible that administration of a P-gp substrate, 
dabigatran with PF‑07321332/ritonavir may lead to changes in exposures of dabigatran.3
Therefore, results of this study will provide guidance for dosing with substrates of P-gp.
The purpose of this study is to estimate the effect of PF-07321332/ritonavir and ritonavir on 
the PK of dabigatran in healthy participants.
Objectives and Endpoints
Objectives
Endpoints
Primary:
Primary:
•
To estimate the effect of the multiple doses of 
PF-07321332/ritonavir co-administered with 
dabigatran orally (test) compared to dabigatran 
administered orally as a single dose (reference).
•
Plasma dabigatran (total) PK parameters: Cmax,
AUCinf (or AUClast if AUCinf cannot be reliably 
estimated).
Secondary: 
Secondary: 
•
To estimate the effect of the multiple doses of 
ritonavir co-administered with dabigatran orally 
(test) compared to dabigatran administered 
orally as a single dose (reference).
•
To evaluate the safety and tolerability of 
dabigatran alone and following
co-administration with multiple dosing of 
PF-07321332/ritonavir or ritonavir
•
To characterize the PK of dabigatran and 
PF-07321332 in study treatments.
•
Plasma dabigatran (total) PK parameters: Cmax,
AUCinf (or AUClast if AUCinf cannot be reliably 
estimated).
•
Safety: TEAEs, clinical laboratory tests, vital 
signs, PE, and ECGs.
•
Dabigatran (total): Tmax, t½, as data permit
•
PF-07321332: Cmax, AUCtau, Tmax, t½, CL/F, 
Vz/F.
 
 
Overall Design
Brief Summary
This is a Phase 1, open-label, randomized, 3-treatment, 6-sequence, 3-way crossover design 
to estimate the effect of PF-07321332/ritonavir and ritonavir on the PK of dabigatran in 
healthy participants. A total of approximately 24 healthy male and/or female participants will 
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 11
be enrolled into the study. The purpose of this study is to estimate the effect of 
PF-07321332/ritonavir and ritonavir on the PK of dabigatran in healthy participants. Safety 
and tolerability will also be assessed throughout the duration of the study. This study will 
consist of 3 treatments. Treatment 1 (T1) will include administration of dabigatran 
administered as a 75 mg single oral dose on Day 1 followed by a 3-day washout. Treatment 2 
(T2) will include multiple dose administration of PF-07321332/ritonavir 300 mg/100 mg 
q12h for 2 days (Days 1 and 2). On the second day of T2 (Day 2) in the morning, a single 
oral dose of dabigatran 75 mg will be administered, followed by a 3-day washout. 
Treatment 3 (T3) will include multiple dose administration of ritonavir 100 mg q12h for 2 
days (Days 1 and 2). On the second day (Day 2) in the morning, dabigatran will be 
administered as a single oral 75 mg dose. PK sampling over 48 hours will be included in all 
3 treatments to determine PK parameters. Each washout period will begin after the first dose 
of study treatment in that treatment period.
Each participant will be screened to determine eligibility within 28 days prior to study 
treatment. Eligible participants will report to the CRU at least 12 hours prior to Day 1 dosing 
in Period 1 and will be required to stay in the CRU for 13 days and 12 nights.
The following describes the study design as an example for Sequence 1 (T1-T2-T3):
Participants in T1 (Day 1) will receive dabigatran orally administered as a 75 mg dose 
followed by a 3-day washout. Serial PK samples will be collected up to 48 hours after single 
dose administration to determine PK parameters. 
T2 will begin on Study Day 5 (referred to as T2 Day 1). Participants in T2 (Day 1) will 
receive multiple doses of PF-07321332/ritonavir 300 mg/100 mg q12h on Days 1 and 2 
followed by a single dose of 75 mg dabigatran administered orally on Day 2, followed by a 
3-day washout. Serial PK samples will be collected up to 48 hours following the 
administration of PF-07321332/ritonavir co-administered with a single oral dose of 75 mg 
dabigatran. 
T3 will begin on Study Day 10 (referred to as T3 Day 1). Participants in T3 (Day 1) will 
receive multiple dose administration of ritonavir 100 mg q12h on Days 1 and 2. On Day 2, 
participants will be administered a single oral 75 mg dose of dabigatran. Serial PK samples 
will be collected up to 48 hours following the administration of ritonavir 100 mg q12h 
co-administered with a single oral dose of 75 mg dabigatran. 
Eligible participants will be admitted to the CRU on Day -1 (at least 12 hours prior to Day 1 
dosing of dabigatran dosing on Day 1) and will be confined in the CRU for 13 days and 
12 nights. On the morning of Day 1 (T1), the participants will receive a single oral dose of 
75 mg of dabigatran administered orally, followed by a 3-day washout. Serial blood samples 
at specified intervals will be collected up to 48 hours post-dose for PK assessments. On the 
morning of Day 1 and Day 2 in T2, PF-07321332/ritonavir 300 mg/100 mg will be 
administered as multiple doses q12h. Dabigatran 75 mg will be administered orally, as a 
single dose on Day 2. On the morning of Day 1 and Day 2 in T3 participants will receive 
multiple dosing of ritonavir 100 mg q12h. On Day 2 of T3, participants will receive 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 12
administration of a single oral dose of 75 mg dabigatran. Serial blood samples at specified 
intervals will be collected up to 48 hours post-dose for PK assessments of both ritonavir and 
dabigatran. Each washout period will begin after the first dose of study treatment in that
treatment period.
All study treatments, regardless of dosing regimen should be administered in the fasting 
condition. Specifically, morning doses should be followed by an overnight fast of 
approximately 8-10 hours. When PK is performed after the morning dose, a 4-hour fast 
should occur. Evening dose will be administered 1 hour before or 2 hours after a meal.  
Safety assessments will be performed during Screening, on Day -1 prior to dosing, and at 
specified time points. PEs, vital sign measurements, and clinical laboratory tests will be 
conducted, and AEs will be monitored to assess safety. The total participation time (eg, CRU 
confinement time for study procedures) for each participant in this study is approximately 
13 days/12 nights (excluding screening and follow-up contact). 
A safety follow-up call will be made to participants 28 to 35 days from administration of the 
final dose of study intervention.
Number of Participants
Approximately 24 participants may be enrolled to study intervention. 
Note: “Enrolled” means a participant, or his or her legally authorized representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process and screening. A participant will be considered enrolled if the informed consent is 
not withdrawn prior to participating in any study activity after screening. Potential 
participants who are screened for the purpose of determining eligibility for the study, but do 
not participate in the study, are not considered enrolled, unless otherwise specified by the 
protocol.
Intervention Groups and Duration
Each participant will be screened to determine eligibility within 28 days prior to study 
treatment. Eligible participants will report to the CRU at least 12 hours prior to Day -1 and 
will be required to stay in the CRU for 13 days and 12 nights. A safety follow-up call will be 
made to participants approximately 28 to 35 days from administration of the final dose of 
study intervention. 
Each enrolled participant will participate in 3 treatments and each washout period will begin 
after the first dose of study treatment:

Treatment 1: In Treatment 1, dabigatran will be administered orally as a 75 mg single 
dose in the morning followed by a 3-day washout.  

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 13

Treatment 2: In Treatment 2, PF-07321332/ritonavir 300 mg/100 mg q12h will be 
administered as multiple doses over a period of 2 days. Morning and evening doses 
will be administered on Day 1, but only the morning dose will be administered on 
Day 2. In the morning on Day 2, 75 mg of dabigatran will be administered orally as a 
single dose. Treatment 2 will be followed by a 3-day washout.

Treatment 3: In Treatment 3, ritonavir 100 mg q12h will be administered as multiple 
doses over a period of 2 days. Morning and evening doses will be administered on 
Day 1, but only the morning dose will be administered on Day 2. In the morning on 
Day 2, 75 mg of dabigatran will be administered orally as a single dose.
Participants will randomly be assigned to 1 of 6 sequences as follows: 
Period 1
Period 2
Period 3
Sequence 1
Treatment 1
Treatment 2
Treatment 3
Sequence 2
Treatment 3
Treatment 1
Treatment 2
Sequence 3
Treatment 2
Treatment 3
Treatment 1
Sequence 4
Treatment 3
Treatment 2
Treatment 1
Sequence 5
Treatment 2
Treatment 1
Treatment 3
Sequence 6
Treatment 1
Treatment 3
Treatment 2
Participants will be discharged in T3, Study Day 13 following completion of all assessments. 
The total planned duration of participation, from the Screening visit to the last Follow-up 
phone call, is approximately 11 weeks.
Data Monitoring Committee or Other Independent Oversight Committee: No
Statistical Methods
A sample size of approximately 24 participants will provide adequate precision to estimate 
the effects of multiple dose PF-07321332/ritonavir on the PK of single dose dabigatran. The 
expected widths of the 90% CIs with 80% coverage probability are shown in the following 
table for a range of possible effects. 
Parameter
Estimated Effect 
(100*Test/Reference)
90% CI
CI Width
AUCinf
80%
100%
120%
140%
63.09%, 101.45%
78.86%, 126.81%
94.63%, 152.17%
110.40%, 177.53%
38.36%
47.95%
57.54%
67.13%

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 14
Parameter
Estimated Effect 
(100*Test/Reference)
90% CI
CI Width
160%
180%
126.17%, 202.89%
141.95%, 228.26%
76.72%
86.31%
Cmax
80%
100%
120%
140%
160%
180%
60.49%, 105.80%
75.61%, 132.25%
90.74%, 158.70%
105.86%, 185.15%
120.98%, 211.60%
136.10%, 238.06%
45.31%
56.64%
67.97%
79.30%
90.62%
101.95%
These estimates are based on the assumption that within-participant standard deviations are 
0.452 and 0.532 for lnAUCinf and lnCmax, respectively, as obtained from the mean of 
2 clinical studies (B1871043 and B7451026) and literature4 in healthy participants.
Participants who withdraw from the study may be replaced at the discretion of the 
investigator upon consultation with the sponsor.
Pharmacokinetics Analysis
The PK concentration population is defined as all participants assigned to investigational 
product and treated who have at least 1 concentration measured.
The PK parameter analysis population is defined as all participants assigned to 
investigational product and treated who have at least 1 of the PK parameters of primary 
interest measured.
Pharmacokinetic parameters for PF-07321332, ritonavir and dabigatran (total) will be 
analyzed by standard noncompartmental method of analysis. Actual PK sampling times will 
be used in the derivation of PF-07321332, ritonavir and dabigatran PK parameters. The PF-
07321332, ritonavir and dabigatran plasma PK parameters will be summarized descriptively 
by treatment. Plasma concentrations will be listed and summarized descriptively by treatment 
and nominal PK sampling time. Individual participant and summary profiles (mean and 
median plots) of the plasma concentration time data will be plotted using actual and nominal 
times, respectively. Box and whisker plots of AUCinf, AUCtau and Cmax will be plotted by 
treatment. 
Drug-Drug Interaction
Natural log transformed parameters (AUCinf [if data permit], AUClast and Cmax) of dabigatran 
will be analyzed using a mixed effect model with treatment, period and sequence as fixed 
effects and participant within sequence as a random effect. Estimates of the adjusted mean 
differences (Test-Reference) and corresponding 90% CIs will be obtained from the model. 
The adjusted mean differences and 90% CIs for the differences will be exponentiated to 
provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CI for 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 15
the ratios. Dabigatran administered alone will be the reference treatment and 
PF-07321332/ritonavir co-administered with dabigatran and ritonavir co-administered with 
dabigatran will be the test treatments. 
Safety Analysis 
AEs, ECGs, vital signs (BP, pulse rate, RR and temperature) and safety laboratory data will 
be reviewed and summarized on an ongoing basis during the study to evaluate the safety of 
participants. Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential 
clinical concern will be described. Safety data will be presented in tabular and/or graphical 
format and summarized descriptively, where appropriate.
1.2. Schema
The following schematic represents the study design as an example for Sequence 1.
Sequence 1
Period 1
Period 2
Period 3
Screening
Days -28 to -2
Treatment 1
(Days 1 and 2)
3-Day 
washouta
Treatment 
2
(Days 1 
and 2)
3-Day 
washouta
Treatment 
3
(Days 1
and 2)
Follow-
up
Days 
28-35
(Reference)
75 mg single oral 
dose of dabigatran
(Test)
PF-
07321332 
/ritonavir 
300/100 mg 
q12h 
multiple 
doses on 
Days 1 and 
2.b On Day 
2, a single 
oral 75 mg 
dose of 
dabigatran  
(Test)
Ritonavir 
100 mg 
q12h on 
Days 1 and 
2.b On Day 
2, a single 
oral dose 
of 75 mg 
dose of 
dabigatran
a.
The 3-day washout will begin after the first dose of study medication.
b.
Morning and evening doses will be administered on Day 1, but only the morning dose will be 
administered on Day 2. 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 16
1.3. Schedule of Activities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evaluations or 
assessments required to protect the well-being of the participant.
All SoA/PK sampling schedules below do not include days of washout.
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 9.
Screeninga
Treatment (See Detailed SoAs Below for Each Treatment)
Follow-Up 
Early 
Termination/
Discontinuation
Days Relative to Day 1 of 
Period 1
Day -28 to 
Day -2
Day -1
Day 13
28-35 Daysb
Hours After Dose
Informed consent
X
CRU confinementc
X







X
Inclusion/exclusion criteria
X
X
Medical/medication history 
(update)d
X
X
Physical examinatione
X
X
X
Safety laboratoryf
X
X
X
TSH & Free T4
X
X
Demographyg
X
Pregnancy test (WOCBP only)
X
X
X
X
Contraception checkh
X
X
X
X
X
FSHi
X
Urine drug testingj
X
X
12-Lead ECGk
X
X
X
Vital signs 
(BP/PR/RR/temperature)l
X
X
X
HIV, HBsAg, HBsAb, HBcAb, 
HCVAb 
X

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 17
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 9.
Screeninga
Treatment (See Detailed SoAs Below for Each Treatment)
Follow-Up 
Early 
Termination/
Discontinuation
Days Relative to Day 1 of 
Period 1
Day -28 to 
Day -2
Day -1
Day 13
28-35 Daysb
Hours After Dose
COVID-19 questionnairem
X
X
COVID-19 testingn
X
X
COVID-19 check temperatureo
X
X
X
X
X
Study intervention 
administrationp
PK blood samplingq
X
Blood/Plasma ratio sampler
 
CRU discharge 
X
Serious and nonserious AE 
monitoring
X
→
→
→
→
→
→
→
→
→
→
→
a.
Screening will be performed within 28 days prior to the first dose of study intervention. 
b.
Contact may occur via telephone contact and must occur 28 to 35 days from administration of the final dose of study intervention.
c.
Participants will be admitted to the CRU on Day -1. Participants will be discharged on Day 13 following the final assessments. 
d.
Medical history will include a history of prior illegal drug, alcohol, and tobacco use, as well as blood donation within prior 60 days. Medical history will be 
recorded at Screening and updated on Day -1 of Period 1. 
e.
A PE will be performed by trained medical personnel at the investigator site at Screening and Day -1 of Period 1 only (height and weight must be obtained 
at Screening to obtain BMI for eligibility criteria) and at Early Termination/Discontinuation. A brief PE may be performed at other designated time points 
at the discretion of the investigator. 
f.
Safety laboratory assessments including urinalysis, hematology, chemistry and coagulation will be performed at the indicated time points. All the safety 
laboratory samples must be collected following at least a 4-hour fast. Additional safety laboratory assessments may be performed at any time at the 
discretion of the investigator. 
g.
Demographics will include participant race, ethnicity, age, and gender during the Screening visit. 
h.
The investigator or his/her designee will discuss with the participant the need to use highly effective contraception consistently and correctly according to 
contraception guidelines.
i.
For postmenopausal (amenorrheic for at least 12 consecutive months) female participants only.
j.
Urine drug (mandatory) and alcohol breath test (at discretion of investigator) will be performed at Screening and on Day -1. These tests may be performed 
at any other time at the discretion of the investigator.
k.
Triplicate 12-lead ECG readings will be taken at specified times. All ECG assessments will be made after at least a 10-minute rest in a supine position and 
prior to any blood draws or vital sign measurements. ECG assessment should be taken in the morning with vitals. 
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 18
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 9.
Screeninga
Treatment (See Detailed SoAs Below for Each Treatment)
Follow-Up 
Early 
Termination/
Discontinuation
Days Relative to Day 1 of 
Period 1
Day -28 to 
Day -2
Day -1
Day 13
28-35 Daysb
Hours After Dose
l.
Single supine BP, RR and PR will be performed following at least a 5-minute rest in a supine position. BP, RR and PR assessments will be performed after 
collection of ECGs and prior to collection of blood draws if scheduled at the same time.
m. Check exposure to positive participant, residence or travel in area of high incidence and COVID-19 related signs and symptoms. To be done at Screening 
and no more than 48 hours before confinement to the CRU.
n.
The testing for COVID-19 pathogen by RT-PCR will be performed at specified times while the participant is admitted for residence. For participants, a 
COVID-19 test will be performed after 4 days (ie, upon completion of 4 × 24 hours in house), or if they develop COVID-19 like symptoms.
o.
To be done at least daily during residence. 
p.
Please see the treatment tables below. 
q.
Please see the PK sampling schedule tables below. PK samples should be collected at time of early termination/discontinuation
r.
Please see the Treatment 2 table below. 
 
C
C
I

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 19
A. Treatment 1 (Single oral dose of dabigatran): Screening – Day 3
Visit Identifier
Abbreviations used in this table may be found in 
Appendix 9.
Schedule for Treatment 1
Days Relative to Day 1
Day 1
Day 2
Day 3
Safety laboratory (including Fibrinogen)a
X
X
aPTT, PT-INR 
X
X
X
TSH & Free T4
X
X
12-lead ECGb
X
X
Vital signs (BP/PR/RR/temperature)c
X
X
COVID-19 questionnaired
COVID-19 testinge
X
COVID-19 check temperaturef
X
X
X
Dabigatran administrationg
X
PK blood sampling for dabigatran (total)h
X
X
X
a.
Safety laboratory assessments including urinalysis, hematology, and chemistry will be performed at the indicated timepoints. All the safety laboratory 
samples must be collected following at least a 4 hour fast. Additional safety laboratory assessments may be performed at any time at the discretion of the 
investigator. 
b.
All ECG assessments (triplicate) will be made after at least a 10-minute rest in a supine position and prior to any blood draws or vital sign measurements.
ECG assessment should be taken in the morning with vitals.
c.
Single supine blood pressure and pulse rate will be performed following at least a 5-minute rest in a supine position. BP and PR assessments will be 
performed after collection of ECGs and prior to collection of blood draws if scheduled at the same time. RR will also be evaluated. Vitals should be taken in 
the morning with ECG assessments.
d.
Check exposure to positive participant, residence or travel in area of high incidence and COVID-19 related signs and symptoms. To be done at Screening 
and no more than 48 hours before confinement to the CRU.
e.
The testing for COVID-19 pathogen by RT-PCR or rapid testing via Abbott ID will be performed at specified times while the participant is admitted for 
residence. For participants, a COVID-19 test will be performed after 4 days (ie, upon completion of 4 × 24 hours in house), or if they develop COVID-19 
like symptoms.
f.
To be done at least daily during residence.
g.
Dabigatran will be administered orally as a single dose. Dabigatran should be administered in the fasting condition (no food or drink except water).
h.
One (approximately 4 mL) blood sample for PK analysis of dabigatran (total) will be taken at the following timepoints: Day 1 pre-dose, and at 1, 2, 4, 6, 8, 
12, 16, 24, 36 and 48 hours post-dose.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 20
Treatment 1 (Single oral dose of dabigatran): PK Sampling Schedule (Days 1-3)
Visit Identifier
Treatment 1 on PK Days
Study Day
Day 1
Day 2
Day 3
Planned Hours Post Morning Dose
0a
1
2
4
6
8
12
16
24
36
48
Study intervention administration
X
PK blood sampling for dabigatran 
(total)
X
X
X
X
X
X
X
X
X
X
X
12-lead ECG
X
X
X
Vital Signs (BP/PR/RR/Temperature)
X
X
X
a.
Predose sample collection.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 21
B. Treatment 2 (PF-07321332/ritonavir with dabigatran): Days 1-4
Visit Identifier
Abbreviations used in this table may be found in Appendix 9.
Schedule for Treatment 2
Days Relative to Day 1
Day 1
Day 2
Day 3
Day 4
Safety laboratory (including Fibrinogen)a
X
X
TSH & Free T4
X
X
aPTT, PT-INR 
X
X
X
12-lead ECGb
X
X
Vital signs (BP/PR/RR/temperature)
X
X
COVID-19 testingc
X
COVID-19 check temperatured
X
X
X
X
Dabigatran administratione
X
PF-07321332/ritonavir administratione
X (am/pm)
X (am only)
PK Blood Sampling for dabigatran (total)f
X
X
X
PK Blood Sampling for PF-07321332 and ritonavirg
X
Blood/plasma ratio samplei
X
a.
Safety laboratory assessments including urinalysis, hematology, and chemistry will be performed at the indicated timepoints. All the safety laboratory samples must be 
collected following at least a 4 hour fast. Additional safety laboratory assessments may be performed at any time at the discretion of the investigator. 
b.
All ECG assessments (triplicate) will be made after at least a 10-minute rest in a supine position and prior to any blood draws or vital sign measurements. ECG assessments 
should be taken in the morning with vital signs.
c.
The testing for COVID-19 pathogen by RT-PCR or rapid testing via Abbott ID will be performed at specified times while the participant is admitted for residence. For 
participants, a COVID-19 test will be performed after 4 days (ie, upon completion of 4 × 24 hours in house), or if they develop COVID-19 like symptoms.
d.
To be done at least daily during residence.
e.
On the morning of Day 2 (T2), dabigatran will be administered orally as a single dose. Dabigatran should be administered in the fasting condition (no food or drink except 
water). On T2 Day 1 and Day 2 following an approximately 8-10-hour fasting period, PF-07321332/ritonavir 300 mg/ 100 mg will be co-administered q12h as multiple doses
in the fasting condition.
f.
One (approximately 4 mL) blood sample for PK analysis of dabigatran (total) will be taken at the following timepoints: Treatment 2 Day 2 (Study Day 6) pre-dose, and at 1, 
2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose.
g.
One (approximately 4 mL) blood sample for PK analysis of PF-07321332 and ritonavir will be taken at the following timepoints: Treatment 2 Day 2 (Study Day 6) pre-dose, 
and at 1, 2, 4, 6, 8, 12 hours post-dose. 
i.
Whole blood sample/aliquot (approximately 150 μL) for in vivo blood/plasma ratio assessment.
CCI
C
C

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 22
Treatment 2 (PF-07321332/ritonavir with dabigatran): PK Sampling Schedule (Days 1-4)
Visit Identifier
Treatment 2 on PK Days
Day 1
Day 2
Day 3
Day 4
Planned Hours Post Morning 
Dose
0a
1
2
4
6
8
12
16
0a
1
2
4
6
8
12
16
24
36
48
PF-07321332/ritonavir
administration
X
X
X
Dabigatran administration
X
PK blood sampling for 
PF-07321332/ritonavir
X
X
X
X
X
X
X
PK blood sampling for 
dabigatran (total)
X
X
X
X
X
X
X
X
X
X
X
12-lead ECG
X
X
X
X
Vital Signs 
(BP/PR/RR/Temperature)
X
X
X
X
 
Blood/Plasma ratio samplec
X
a.
Pre-dose sample
c.
Whole blood sample/aliquot (approximately 150 μL) for in vivo blood/plasma ratio assessment.
CCI
C
C

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 23
C. Treatment 3 (Ritonavir with dabigatran): Days 1-4
Visit Identifier
Abbreviations used in this table may be found in 
Appendix 9.
Schedule for Treatment 3
Days Relative to Day 1
Day 1
Day 2
Day 3
Day 4
Safety laboratory (including Fibrinogen)a
X
X
aPTT, PT-INR 
X
X
X
X
TS4 & Free T4
X
X
12-lead ECGb
X
X
Vital signs (BP/PR/RR/temperature)c
X
X
X
COVID-19 testingd
X
COVID-19 check temperaturee
X
X
X
X
Dabigatran administrationf
X
Ritonavir administrationg
X (am/pm)
X (am only)
PK blood sampling for dabigatran (total)h
X
X
X
a.
Safety laboratory assessments including urinalysis, hematology, and chemistry will be performed at the indicated timepoints. All the safety laboratory 
samples must be collected following at least a 4 hour fast. Additional safety laboratory assessments may be performed at any time at the discretion of the 
investigator.
b.
All ECG assessments (triplicate) will be made after at least a 10-minute rest in a supine position and prior to any blood draws or vital sign measurements.
ECG assessments should be taken in the morning with vitals.
c.
Single supine BP and PR will be performed following at least a 5-minute rest in a supine position. BP and PR assessments will be performed after collection 
of ECGs and prior to collection of blood draws if scheduled at the same time. RR will also be evaluated. Vitals should be taken in the morning with ECG 
assessments.
d.
The testing for COVID-19 pathogen by RT-PCR or rapid testing via Abbott ID will be performed at specified times while the participant is admitted for 
residence. For participants, a COVID-19 test will be performed after 4 days (ie, upon completion of 4 × 24 hours in house), or if they develop COVID-19 
like symptoms.
e.
To be done at least daily during residence.
f.
Dabigatran will be administered orally as a single dose. Dabigatran should be administered in the fasting condition (no food or drink except water).
g.
In T3 Day 1 and Day 2, participants will receive multiple dosing of ritonavir 100 mg q12h the fasting condition over a period of 2 days.
h.
One (approximately 4 mL) blood sample for PK analysis of dabigatran (total) will be taken at the following timepoints in T3: Day 2 pre-dose, and at 1, 2, 4, 
6, 8, 12, 16, 24, 36 and 48 hours post-dose.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 24
Treatment 3 (Ritonavir with dabigatran): PK Sampling Schedule (Days 1-4)
Visit Identifier
Treatment 3 on PK Days
Day 1
Day 2
Day 3
Day 4
Planned Hours Post 
Morning Dose
0a
1
2
4
6
8
12
16
0a
1
2
4
6
8
12
16
24
36
48
Ritonavir administration
X
X
X
Dabigatran administration
X
PK blood sampling for 
dabigatran (total)
X
X
X
X
X
X
X
X
X
X
X
12-lead ECG
X
X
X
X
Vital Signs 
(BP/PR/RR/temperature)
X
X
X
X
a.
Pre-dose sample.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 25
2. INTRODUCTION
PF-07321332 is a potent and selective inhibitor of the SARS-CoV-2 3CL protease that is 
currently being developed as an oral treatment of COVID-19. Ritonavir is a strong CYP3A4 
inhibitor being used to inhibit the metabolism of PF-07321332 in order to increase plasma 
concentrations of PF-07321332 to values that are anticipated to be efficacious. 
2.1. Study Rationale 
In vitro and in vivo metabolite profiling suggests that the primary clearance mechanism for 
PF-07321332 is CYP3A4 mediated oxidation. In a reaction phenotyping study using human 
liver microsomes in the presence of selective CYP inhibitors, CYP3A4 was predicted to be 
the major contributor (fm = 0.99) to the in vitro oxidative metabolism of PF-07321332. As 
such, in the FIH study, C4671001, the CYP3A4 inhibitor ritonavir was used to enhance the 
exposure of PF-07321332 in order to achieve plasma levels that are anticipated to be 
efficacious. Preliminary PK data following multiple oral administrations of 
PF‑07321332/ritonavir at doses of 75/100 mg, 250/100 mg, and 500/100 mg q12h suggest 
that the renal pathway may also play a significant role in PF-07321332 excretion when 
co-administered with ritonavir, with approximately 32.5% (PF‑07321332/ritonavir 
500/100 mg) to 64.6% (PF‑07321332/ritonavir 75/100 mg) of the drug excreted unchanged 
in urine across doses at steady-state, and renal clearance ranging between 3.5 to 4.4 L/h 
across doses. Ritonavir is extensively metabolized, primarily by CYP3A4.1
The DDI potential of PF-07321332 was further evaluated using a static mechanistic model
using the projected Cmax for reversible inhibition or Cav time-dependent inhibition in plasma,
intestinal lumen, enterocytes, liver, and portal inlet (incorporating kp,uu and ka). Based on this
model, PF-07321332 has minimal risk to inhibit CYPs other than 3A4, UGTs and transport 
proteins: however, the potential remains to reversibly and time-dependently inhibit CYP3A4 
and inhibit P-gp in humans at the proposed therapeutic dose. 
Dabigatran etexilate (herein referred to as dabigatran) is a sensitive probe substrate of the 
efflux transporter P-gp that experiences a ≥2-fold increase in exposure upon coadministration 
with P-gp inhibitors verapamil or quinidine.2  Additionally, dabigatran is primarily renally 
eliminated by glomerular filtration (approximately 80%).2
Ritonavir is classified as a P-gp inhibitor. Although limited clinical data exists on drug-drug 
interactions with ritonavir and P-gp probe substrates like dabigatran, results from one study 
assessing the concomitant administration of dabigatran etexilate and ritonavir did not result 
in statistically significant changes in any of the PK parameters of dabigatran or changes in 
thrombin time measures as compared to dabigatran administered alone. However, there was 
statistically significant and similar decreases in the dabigatran AUC and Cmax when 
dabigatran and ritonavir were administered separately by 2 hours compared to values 
obtained when dabigatran was administered alone, suggesting there may be the potential of 
ritonavir to induce P-gp. Even though dabigatran is primarily renally eliminated, results 
suggested that whether dabigatran and ritonavir were administered simultaneously or 
separated by 2 hours, there was no change in dabigatran t½ or Kel compared to dabigatran 
administered alone.2

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 26
Based on available data to date, it is possible that administration of a P-gp substrate, 
dabigatran with PF‑07321332/ritonavir may lead to further changes in exposures of 
dabigatran.3 Therefore, results of this study will provide guidance for dosing with substrates 
of P-gp.
The purpose of this study is to estimate the effect of PF-07321332/ritonavir and ritonavir on 
the PK of dabigatran in healthy participants.
2.2. Background 
In December 2019, COVID-19 was identified as a new, potentially fatal, respiratory infection 
caused by the novel coronavirus, SARS-CoV-2. The WHO declared COVID-19 a Public 
Health Emergency of International Concern on 20 January 2020 and further characterized the 
disease outbreak as a pandemic on 11 March 2020.5
PF-07321332 is an orally bioavailable 3CLpro inhibitor shown to be effective against 
SARS-CoV-2 3CLpro (Ki = 0.00311 µM) in a biochemical enzymatic assay. Since the 
3CLpro from human coronaviruses are structurally similar and share a high degree of 
conservation at the active site of the enzyme, the ability of PF-07321332 to inhibit the 3CLpro 
of other coronaviruses (SARS-CoV-1 and HcoV-229E, MERS, HcoV-OC43, HcoV-HKU1, 
and HcoV-NL63) was also confirmed, indicating a potential for broad spectrum anti-
coronavirus activity. The coronavirus 3CL protease is a virally encoded enzyme that is 
critical to the SARS-CoV-2 replication cycle, analogous to other obligatory virally encoded 
proteases (eg, HIV Protease, HCV Protease).6 PF-07321332 is being developed as an oral 
treatment in patients with COVID-19 infection. 
Ritonavir is a strong CYP3A4 inhibitor being used to inhibit the metabolism of PF-07321332 
in order to increase plasma concentrations of PF-07321332 to values that are anticipated to 
be efficacious. Ritonavir is not expected to have any pharmacological impact on the 
SARS-CoV-2 virus. Ritonavir is being used only as a pharmacokinetic boosting agent.
2.2.1. Nonclinical Pharmacology
Details of the nonclinical pharmacology of PF-07321332 can be found in the current IB.
2.2.2. Nonclinical Pharmacokinetics and Metabolism
Hepatic CYP3450 enzymes were identified as the main pathway for clearance of 
PF-07321332 in vitro in liver microsomes (mouse, rat, hamster, rabbit, monkey, and human), 
hepatocytes (rat, monkey, and human), and in vivo in rat and monkey after repeat oral dosing 
(Study PF-07321332_09Nov20_084546). In a reaction phenotyping study using human liver 
microsomes in the presence of selective CYP inhibitors, CYP3A4 was predicted to be the 
major contributor (fm = 0.99) to the in vitro oxidative metabolism of PF-07321332. No 
significant CYP3A5 contribution is expected to the metabolism of PF-07321332. 
(Study PF-07321332_21Nov20_072016). Urinary excretion of PF-07321332 following 
single IV or oral doses in rats was approximately 11%, suggesting minor urinary 
contributions to the overall elimination of PF-07321332. 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 27
Additional information of the nonclinical PK and metabolism of PF-07321332 is available in 
the current IB.
2.2.3. Nonclinical Safety
There were no adverse findings observed in repeat-dose toxicity studies in rats and monkeys 
up to 2 weeks duration and the NOAELs were the highest dose administered (1000 mg/kg 
and 75 mg/kg in the rat and monkey studies, respectively). PF-07321332-related 
non-adverse, test article-related clinical findings included sporadic occurrence of emesis with 
slight body weight decreases in monkeys. Monitorable and reversible clinical pathology
findings included those possibly suggestive of low-grade inflammation (in rats and monkeys) 
or alterations in the coagulation pathways (in rats only) without clinical or microscopic 
correlates. Other non-adverse clinical pathology findings were likely due to the emesis and 
subsequent dehydration in monkeys. In rats administered 1000 mg/kg/day, lower mean 
absolute and relative heart weights (females) and higher absolute and relative liver weights 
(both sexes) were observed relative to controls. The lower heart weights had no microscopic 
correlates and were fully reversed at the end of the 2-week recovery period. Higher liver 
weights correlated with reversible, non-adverse microscopic findings of minimal to mild 
severity in the liver and thyroid gland consistent with adaptive changes related to microsomal 
enzyme induction.

PF-07321332 was not mutagenic or clastogenic in in vitro genetic toxicity studies and 
was negative in the in vivo rat micronucleus assay incorporated into the GLP 
repeat-dose rat toxicity study. 

The nonclinical studies performed adequately support the oral administration of 
PF-07321332 in the clinic for up to 14 days.
Further details of the nonclinical safety program are provided in the current IB.
2.2.4. Clinical Overview
Safety, tolerability and pharmacokinetics of PF-07321332 in healthy adult participants is 
currently being explored in an ongoing Phase 1 FIH study (C4671001). Prior to 
Amendment 3, Study C4671001 is a 4-part study consisting of SAD (PART-1), MAD 
(PART-2), relative bioavailability/food effect (PART3), and metabolism and excretion study 
(PART-4). PART-1 and -2 are randomized, double-blind, sponsor-open, and placebo 
controlled to evaluate safety, tolerability, and PK of single and multiple escalating oral doses 
of PF-07321332, respectively. PART-3 is randomized and open-label to evaluate relative 
bioavailability and food effect of an oral tablet formulation. PART-4 is an open-label, 
non-randomized, single period to evaluate the metabolism and excretion of PF-07321332. 
Included in this Clinical Overview are summaries of the preliminary results from PART-1 
and PART-2. 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 28
2.2.4.1. Safety Overview
Preliminary safety and tolerability data from Study C4671001 as of 07 April 2021 in PART-1 
and 14 April 2021 in PART-2 (data snapshot taken) demonstrated PF-07321332 was 
generally safe and well-tolerated in healthy participants at single doses of PF-07321332 
ranging from 150 mg to 1500 mg alone and at 250 mg and 750 mg with ritonavir (100 mg at 
-12h, 0h, 12h) in the PART-1: SAD, and 10 days of dosing from 75 mg BID to 500 mg BID 
with 100 mg ritonavir BID in the PART-2: MAD of the study. 
Following single doses of PF-07321332 with and without ritonavir, all AEs were mild and 
none was considered treatment related. There were no obvious trends in, or association of, 
TEAEs with any dose level of PF-07321332. Following multiple doses, the most commonly 
observed AEs by system organ class were gastrointestinal disorders and nervous system 
disorders. Diarrhea was the most common reported AE, occurring in 4 participants across 
treatment groups. A total of 5 treatment related TEAEs were observed in Part-2: MAD. 
Across treatment groups, blood TSH increased in 3 participants, and 2 participants reported 
dysgeusia. The 3 participants with elevated TSH results did not experience related clinical 
symptoms and the free T4 results remained within reference range. 
Based on review of preliminary (unaudited) data, all reported adverse events have been of 
mild intensity. There have been no deaths, serious adverse events, or SUSARs reported. 
There were no clinically meaningful findings in vital signs, ECG, or potential Hy’s Law 
cases reported during this study. 
Further details on the clinical safety information with PF-07321332 are provided in the 
current IB.
2.2.4.2. Summary of PF-07321332 Pharmacokinetics in Human
Preliminary single dose PK data from Study C4671001 at doses of PF-07321332 of 150 mg, 
500 mg, and 1500 mg alone and at 250 mg and 750 mg with ritonavir 100 mg (dosed at -12h, 
0h, and 12h) show that PF-07321332 was absorbed rapidly with median Tmax of 1 hour or 
less when administered alone and 2.75 hours or less when administered with ritonavir. Since 
PF-07321332 is primarily metabolized by CYP3A4 and ritonavir is a CYP3A4 inhibitor, 
dosing with ritonavir increased the exposure of PF-07321332. Highest observed mean Cmax
and AUClast was 5.09 µg/mL and 64.26 µg.h/mL, respectively, at 750 mg PF-07321332 
dosed with ritonavir. The mean half-life of PF-07321332 was approximately 2 hours when 
administered alone and increased to approximately 6-13 hours when co-administered with 
ritonavir. Dosing with a high-fat meal modestly increased the exposure of PF-07321332 
(approximately 15% increase in mean Cmax and 1.6% in mean AUClast). 
Preliminary PK data on Day 1, Day 5 and Day 10 following multiple oral administration of 
PF-07321332/ritonavir 75/100 mg, 250/100 mg, and 500/100 mg BID suggest less than 
proportional increase in exposures at steady state. Multiple dosing over 10 days achieved 
steady state on Day 2 with approximately 2-fold accumulation. Day 5 and Day 10 exposure 
was similar at all doses. Approximately 32.5% to 64.6% of the drug was excreted unchanged 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 29
in urine across different doses at steady-state. The renal clearance ranged between 3.5 to 
4.4 L/h across doses.
Further details on the clinical PK of PF-07321332 are provided in the current IB.
2.3. Benefit/Risk Assessment

PF-07321332/ritonavir alone or in combination with dabigatran is not expected to 
provide any clinical benefit to healthy participants in this study. This study is 
designed primarily to generate safety, tolerability, and pharmacokinetic data for 
further clinical development. 

Based on preliminary data from the ongoing Phase 1 study (C4671001) collected as 
of 07 April 2021 in PART-1 and 14 April 2021 in PART-2 (data snapshot taken), the 
clinical safety profile of PF-07321332 appears to be acceptable at single doses up to 
1500 mg alone and up to 750 mg administered with ritonavir (100 mg 
at -12h, 0h, 12h), and at repeated daily doses administered orally for 10 days of up to 
500 mg PF-07321332 BID with 100 mg ritonavir BID. 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of PF-07321332 may be found in the IB, which is the SRSD for this study. The 
SRSDs for ritonavir7 and dabigatran8 are the corresponding USPIs. 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 30
2.3.1. Risk Assessment
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
Study Intervention(s): PF-07321332
Emesis
Sporadic emesis was observed at ≥100 mg/kg/day of 
PF-07321332 in the 15-day NHP- toxicology study (See IB). 
Based on preliminary data, no emesis was observed in the 
FIH Study C4671001 at single doses of PF-07321332 up to 
1500 mg alone and up to 750 mg administered with ritonavir 
(100 mg at -12h, 0h, 12h), and at repeated daily doses 
administered orally for 10 days of up to 500 mg 
PF-07321332 BID with 100 mg ritonavir BID.
As this is an investigational agent, there is some 
risk that is mitigated by close observation of AEs, 
etc. If needed, palliative care or antiemetics may 
be provided.
Neuronal and pulmonary effects
Transient effect in rat neuronal and pulmonary endpoints 
were observed in rat toxicology study at the high dose level 
(1000 mg/kg as single dose; See IB). Based on preliminary 
data, no AEs suggestive of neuronal or pulmonary effects 
were observed in the FIH Study C4671001 at single doses of 
PF-07321332 up to 1500 mg alone and up to 750 mg 
administered with ritonavir (100 mg at -12h, 0h, 12h), and at 
repeated daily doses administered orally for 10 days of up to 
500 mg PF-07321332 BID with 100 mg ritonavir BID.
Vital signs, including respiratory rate, will be 
monitored for pulmonary effect. There will be 
close observation of AEs for any signs of 
neuronal effect. 
Hemodynamic effects
Low level inflammation (increase in fibrinogen) in 15-day 
NHP toxicology study and changes in platelets, globulin and 
albumin/globulin ratio and coagulation system (increase in 
PT and aPTT) in 14-day rat toxicology study (See IB). No 
relevant laboratory changes in inflammatory markers have 
been observed in the FIH Study C4671001 at single doses of 
PF-07321332 up to 1500 mg alone and up to 750 mg 
administered with ritonavir (100 mg at -12h, 0h, 12h), and at 
repeated daily doses administered orally for 10 days of up to 
500 mg PF-07321332 BID with 100 mg ritonavir BID.
Fibrinogen, platelets, PT-INR and aPTT, albumin 
and total proteins will be monitored. 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 31
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
Thyroid function studies
In 14-day rat toxicology study at high dose of PF-07321332 
(1000 mg/kg/day) thyroid gland changes observed were of 
low severity and without evidence of tissue damage. In the 
FIH Study C4671001, 3 participants had TEAEs of elevated 
TSH levels across treatment groups (PF-07321332 or 
placebo with ritonavir 100 mg BID) in the MAD part of the 
study. There was no clinical correlation with these TSH 
changes and free T4 remained within reference range at all 
times.
TSH and free T4 will be evaluated to monitor 
thyroid function
Study Intervention(s): Ritonavir
Gastrointestinal disturbances (including 
diarrhea, nausea, vomiting and 
abdominal pain).
Frequently reported adverse reaction in HIV patients at 
600 mg BID.
Lower dose of 100 mg twice daily is used in this 
study. There will be close observation of AEs. If 
needed, anti-emetics may be provided. 
Neurological disturbances (eg, 
paresthesia, including oral paresthesia, 
dysgeusia and dizziness).
Frequently reported adverse reaction in HIV patients at 
600 mg BID.
Lower dose used in this study. There will be close 
observation of AEs. 
Rash (most commonly reported as 
erythematous and maculopapular, 
followed by pruritic).
Frequently reported adverse reaction in HIV patients at 
600 mg BID.
Lower dose used in this study. There will be close 
observation of AEs and monitoring through 
targeted physical exams. If needed, palliative care 
may be provided. 
Fatigue/Asthenia
Frequently reported adverse reaction in HIV patients at 
600 mg BID.
Lower dose used in this study. There will be close 
observation of AEs and monitoring through 
targeted physical exams.
Limited case reports of renal toxicity
Although ritonavir therapy is not generally considered 
nephrotoxic, a limited number of cases of acute kidney 
injury secondary to ritonavir have been reported post-
marketing in HIV patients.
Lower dose used in this study. There will be close 
observation of AEs and renal function.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 32
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
Study Intervention (s): Dabigatran
Spinal/Epidural hematoma: 
When spinal/epidural anesthesia or spinal puncture is 
employed patients treated with anticoagulant agents are at 
risk of developing an epidural or spinal hematoma.
Participants are excluded who have had neuraxial 
anesthesia or have undergone spinal puncture
Bleeding which can be serious, and 
sometimes lead to death. This is because 
PRADAXA® is a blood thinner 
medicine that lowers the chance of 
blood clots forming in your body.
Dabigatran increases the risk of bleeding and can cause 
significant and, sometimes, fatal bleeding. Promptly evaluate 
any signs or symptoms of blood loss (eg, a drop in 
hemoglobin and/or hematocrit or hypotension).
Measurement of PT, aPTT, INR throughout all 
3 treatments in the study. In addition, CBC to 
monitor platelets, Hgb, HCT, etc. as well as 
hemodynamic monitoring such as BP and PR are 
also being evaluated in the study.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 33
2.3.2. Benefit Assessment
PF-07321332/ritonavir and dabigatran will not provide any clinical benefit to healthy 
participants in this study. Any anticipated benefit to participants would be in terms of 
contribution to the process of developing a new therapy in an area of unmet medical need.
2.3.3. Overall Benefit/Risk Conclusion
PF-07321332/ritonavir and dabigatran are not expected to provide any clinical benefit to 
healthy participants in this study. Taking into account the measures taken to minimize risk to 
participants of this study, the potential risks identified in association with administration of 
PF-07321332/ritonavir and dabigatran are justified by the anticipated benefit, in terms of 
contribution to the process of developing a new therapy in an area of unmet medical need.
3. OBJECTIVES AND ENDPOINTS
Objectives
Endpoints
Primary:
Primary:
•
To estimate the effect of the multiple doses of 
PF-07321332/ritonavir co-administered with 
dabigatran orally (test) compared to dabigatran 
administered orally as a single dose (reference).
•
Plasma dabigatran (total) PK parameters: Cmax,
AUCinf (or AUClast if AUCinf cannot be reliably 
estimated).
Secondary: 
Secondary: 
•
To estimate the effect of the multiple doses of 
ritonavir co-administered with dabigatran orally 
(test) compared to dabigatran administered 
orally as a single dose (reference).
•
To evaluate the safety and tolerability of 
dabigatran alone and following 
co-administration with multiple dosing of 
PF-07321332/ritonavir or ritonavir
•
To characterize the PK of dabigatran and 
PF-07321332 in study treatments.
•
Plasma dabigatran (total) PK parameters: Cmax,
AUCinf (or AUClast if AUCinf cannot be reliably 
estimated).
•
Safety: TEAEs, clinical laboratory tests, vital
signs, PE, and ECGs.
•
Dabigatran (total): Tmax, t½, as data permit
•
PF-07321332: Cmax, AUCtau, Tmax, t½, CL/F, 
Vz/F.
 
 
 
4. STUDY DESIGN
4.1. Overall Design
This is a Phase 1, open-label, randomized, 3-treatment, 6-sequence, 3-way crossover design 
to estimate the effect of PF-07321332/ritonavir or ritonavir on the PK of a P-gp substrate, 
dabigatran in healthy participants.
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 34
This study will consist of 3 treatments. In T1, dabigatran will be administered orally as a 
75 mg single dose followed by a 3-day washout. In T2, PF-07321332/ritonavir 
300 mg/100 mg q12h will be administered as a multiple dose over a period of 2 days. In the 
morning on Day 2, 75 mg of dabigatran will be administered orally as a single dose. 
Treatment 2 will be followed by a 3-day washout. In T3, ritonavir 100 mg q12h will be 
administered as a multiple dose over a period of 2 days. In the morning on Day 2, 75 mg of 
dabigatran will be administered orally as a single dose. Each washout period will begin after 
the first dose of study treatment. A total of approximately 24 healthy male and/or female 
participants will be enrolled into the study. Participants who discontinue from the study may 
be replaced at the sponsor’s discretion in collaboration with the Investigator. 
The purpose of this study is to estimate the effect of PF-07321332/ritonavir and ritonavir on 
the PK of dabigatran in healthy participants.
Healthy participants (approximately n=24) will be screened to determine eligibility within 28 
days prior to study treatment. Medical history and results of PE, physical measurements, vital 
signs, 12-lead ECGs, and clinical laboratory evaluations will determine eligibility. 
Participants will report to the CRU at least 12 hours prior to Day 1 dosing in T1 and will be 
required to stay in the CRU for 13 days and 12 nights. Each washout period will begin after 
the first dose of study treatment.
Participants will randomly be assigned to 1 of 6 sequences as follows: 
Period 1
Period 2
Period 3
Sequence 1
Treatment 1
Treatment 2
Treatment 3
Sequence 2
Treatment 3
Treatment 1
Treatment 2
Sequence 3
Treatment 2
Treatment 3
Treatment 1
Sequence 4
Treatment 3
Treatment 2
Treatment 1
Sequence 5
Treatment 2
Treatment 1
Treatment 3
Sequence 6
Treatment 1
Treatment 3
Treatment 2
The following describes the study design as an example for Sequence 1 (T1-T2-T3):
Participants in T1 (Day 1) will receive dabigatran orally administered as a 75 mg dose 
followed by a 3-day washout. Serial PK samples will be collected up to 48 hours after single 
dose administration to determine PK parameters. 
T2 will begin on Study Day 5 (referred to as T2 Day 1). Participants in T2 (Day 1) will 
receive multiple doses of PF-07321332/ritonavir 300 mg/100 mg q12h on Days 1 and 2 
followed by a single dose of 75 mg dabigatran administered orally on Day 2. A 3-day 
washout will ensue the co-administration of PF-07321332/ritonavir and dabigatran. Serial PK 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 35
samples will be collected up to 48 hours following the administration of 
PF-07321332/ritonavir co-administered with a single oral dose of 75 mg dabigatran. 
T3 will begin on Study Day 10 (referred to as T3 Day 1). Participants in T3 (Day 1) will 
receive multiple dose administration of ritonavir 100 mg q12h on Days 1 and 2. In the 
morning on Day 2, participants will be administered a single oral 75 mg dose of dabigatran. 
Serial PK samples will be collected up to 48 hours following multiple dose administration of 
ritonavir 100 mg co-administered with a single oral dose of 75 mg dabigatran. 
The total planned duration of participation, from the Screening visit to the last Follow-up 
phone call, is approximately 11 weeks.
Eligible participants will be admitted to the CRU on Day -1 (at least 12 hours prior to Day 1 
dosing of dabigatran dosing on Day 1) and will be confined in the CRU for 13 days and 
12 nights. On the morning of Day 1 (T1), the participants will receive a single oral dose of 
75 mg of dabigatran administered orally, followed by a 3-day washout. Serial blood samples 
at specified intervals will be collected up to 48 hours post-dose for PK assessments. On the 
morning of Day 1 and Day 2 in T2, PF-07321332/ritonavir 300 mg/100 mg will be 
administered as multiple doses q12h. Dabigatran 75 mg will be administered orally, as a 
single dose on Day 2. On the morning of Day 1 and Day 2 in T3 participants will receive 
multiple dosing of ritonavir 100 mg q12h. On Day 2 of T3, participants will receive 
administration of a single oral dose of 75 mg dabigatran. Serial blood samples at specified 
intervals will be collected up to 48 hours post-dose for PK assessments of both ritonavir and 
dabigatran. Each washout period will begin after the first dose of study treatment.
All study treatments, regardless of dosing regimen should be administered in the fasting 
condition. Specifically, morning doses should be followed by an overnight fast of 
approximately 8-10 hours. When PK is performed after the morning dose, a 4-hour fast 
should occur. Evening dose will be administered 1 hour before or 2 hours after a meal.  
Safety assessments will be performed during Screening, on Day -1 prior to dosing, and at 
specified time points. PEs, vital sign measurements, and clinical laboratory tests will be 
conducted, and AEs will be monitored to assess safety. The total participation time (eg, CRU 
confinement time for study procedures) for each participant in this study is approximately 
13 days/12 nights (excluding screening and follow-up contact). Participants will be 
discharged in T3, Study Day 13 following completion of all assessments.
A safety follow-up call will be made to participants approximately 28 to 35 days from 
administration of the final dose of study intervention.
4.2. Scientific Rationale for Study Design
PF-07321332 is a potent and selective inhibitor of the SARS-CoV-2 3CL protease that is 
currently being developed as an oral treatment of COVID-19. Ritonavir is a strong CYP3A4 
inhibitor being used to inhibit the metabolism of PF-07321332 in order to increase plasma 
concentrations of PF-07321332 to values that are anticipated to be efficacious. 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 36
In vitro and in vivo metabolite profiling suggests that the primary clearance mechanism for 
PF-07321332 is CYP3A4 mediated oxidation. In a reaction phenotyping study using human 
liver microsomes in the presence of selective CYP inhibitors, CYP3A4 was predicted to be 
the major contributor (fm = 0.99) to the in vitro oxidative metabolism of PF-07321332. As 
such, in the FIH study, C4671001, the CYP3A4 inhibitor ritonavir was used to enhance the 
exposure of PF-07321332 in order to achieve plasma levels that are anticipated to be 
efficacious. Preliminary PK data following multiple oral administrations of 
PF‑07321332/ritonavir at doses of 75/100 mg, 250/100 mg, and 500/100 mg q12h suggest 
that the renal pathway may also play a significant role in PF-07321332 excretion when 
co-administered with ritonavir, with approximately 32.5% (PF‑07321332/ritonavir 
500/100 mg) to 64.6% (PF‑07321332/ritonavir 75/100 mg) of the drug excreted unchanged 
in urine across doses at steady-state, and renal clearance ranging between 3.5 to 4.4 L/h 
across doses. Ritonavir is extensively metabolized, primarily by CYP3A4.1
The DDI potential of PF-07321332 was further evaluated using a static mechanistic model
using the projected Cmax for reversible inhibition or Cav time-dependent inhibition in plasma,
intestinal lumen, enterocytes, liver, and portal inlet (incorporating kp,uu and ka). Based on this
model, PF-07321332 has minimal risk to inhibit CYPs other than 3A4, UGTs and transport 
proteins; however, the potential remains to reversibly and time-dependently inhibit CYP3A4 
and inhibit P-gp in humans at the proposed therapeutic dose. 
Dabigatran is a sensitive probe substrate of the efflux transporter P-gp that experiences a ≥2-
fold increase in exposure upon coadministration with P-gp inhibitors verapamil or quinidine.2
Additionally, dabigatran is primarily renally eliminated by glomerular filtration 
(approximately 80%).2
Ritonavir is classified as a P-gp inhibitor. Although limited clinical data exists on drug-drug 
interactions with ritonavir and P-gp probe substrates like dabigatran, results from one study 
assessing the concomitant administration of dabigatran etexilate and ritonavir did not result 
in statistically significant changes in any of the PK parameters of dabigatran or changes in 
thrombin time measures as compared to dabigatran administered alone. However, there was 
statistically significant and similar decreases in the dabigatran AUC and Cmax when 
dabigatran and ritonavir were administered separately by 2 hours compared to values 
obtained when dabigatran was administered alone, suggesting there may be the potential of 
ritonavir to induce P-gp. Even though dabigatran is primarily renally eliminated, results 
suggested that whether dabigatran and ritonavir were administered simultaneously or 
separated by 2 hours, there was no change in dabigatran t½ or Kel compared to dabigatran 
administered alone.2
Based on available data to date, it is possible that administration of a P-gp substrate, 
dabigatran with PF‑07321332/ritonavir may lead to changes in exposures of dabigatran.3
Therefore, results of this study will provide guidance for dosing with substrates of P-gp.
Lastly, the rationale to study the effect of ritonavir on dabigatran is for labeling purposes.
Pfizer is pursuing the goal of a label similar to ritonavir with respect to DDIs. If the results 
from this study suggest that there is no influence of ritonavir on dabigatran concentrations as 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 37
compared to PF-07321332/ritonavir, this may be a convincing argument to not pursue 
additional DDI studies and accept the ritonavir label.  
4.2.1. Choice of Contraception/Barrier Requirements 
Human reproductive safety data are limited for PF-07321332, but there is no suspicion of 
human teratogenicity based on the intended pharmacology of the compound. Therefore, the 
use of a highly effective method of contraception is required (see Appendix 4).
 
4.3. Justification for Dose
A dose of 300 mg PF-07321332, pharmacokinetically enhanced with 100 mg ritonavir, to be 
administered as a single dose is planned in this study. This is the anticipated Phase 2/3 dose 
of PF-07321332/ritonavir of 300/100 mg.
When co-administered with ritonavir, doses of PF-07321332 up to 750 mg single dose and 
500 mg q12h for 10 days were generally safe and well tolerated based on preliminary data 
form the Phase 1 Study C4671001. There have been no deaths or serious adverse events or 
SUSARs reported. Based on review of preliminary (unaudited) data, all reported adverse 
events have been of mild intensity. There were no clinically meaningful findings in vital 
signs, ECG, or potential Hy’s Law cases reported during the study. 
The dose of ritonavir to be used in this study is 100 mg administered in combination with 
PF-07321332. This dose is the typical dose of ritonavir when used as a PK enhancer. 
Little research is available to date utilizing dabigatran as a P-gp substrate. Some DDI studies 
available in the published literature utilize a 150 mg single oral dose when using dabigatran 
as a P-gp probe.3 As increases in dabigatran exposure may occur when co-administered with 
PF-07321332/ritonavir or ritonavir alone a single oral dose of 75 mg of dabigatran was 
chosen for this study. 
4.4. End of Study Definition
The end of the study is defined as the date of last scheduled procedure shown in the SoA for 
the last participant in the trial.
A participant is considered to have completed the study if he/she has completed all parts of 
the study, including the last scheduled procedure shown in the SoA.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled. The 
following eligibility criteria are designed to select participants for whom participation in the 
study is considered appropriate. All relevant medical and nonmedical conditions should be 
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 38
taken into consideration when deciding whether a particular participant is suitable for this 
protocol. 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Age and Sex:
1. Male or female participants must be 18 to 60 years of age, inclusive, at the time of 
signing the ICD.
Type of Participant and Disease Characteristics:
2. Male and female participants who are overtly healthy as determined by medical 
evaluation including medical history, PE, laboratory tests, and cardiac monitoring.

Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and 
female (Section 10.4.2) participants
3. Participants who are willing and able to comply with all scheduled visits, treatment 
plan, laboratory tests, and other study procedures.
4. Female participates of childbearing potential must have a negative pregnancy test.
Weight: 
5. BMI of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb). 
Informed Consent:
6. Capable of giving signed informed consent as described in Appendix 1, which 
includes compliance with the requirements and restrictions listed in the ICD and in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
1. Positive test result for SARS-CoV-2 infection at the time of Screening or Day -1.
2. Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 39
allergic disease (including drug allergies, but excluding untreated, asymptomatic, 
seasonal allergies at the time of dosing).
3. Any history of malignancy (with the exception of adequately treated or excised 
non-metastatic basal cell or squamous cell carcinoma of the skin or cervical 
carcinoma in situ).
4. Clinically relevant abnormalities requiring treatment (eg, acute myocardial infarction, 
serious tachy- or brady-arrhythmias) or indicating serious underlying heart disease 
(eg, prolonged PR interval, cardiomyopathy, underlying structural heart disease, 
Wolff Parkinson–White syndrome). 
5. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy)
6. History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HbsAb, 
HbsAg, HbcAb, or HCVAb. Hepatitis B vaccination is allowed.
7. Any conduction abnormality (including but not specific to left or right complete 
bundle branch block, or AV block [2nd degree or higher]).  
8. Having undergone neuraxial intervention or undergoing spinal puncture 12 weeks
prior to study start or planned neuraxial intervention or spinal puncture within 12
weeks after the end of the study.
9. Active pathological bleeding or risk of bleeding including prior personal or familiar 
history of abnormal bleeding, hereditary or acquired coagulation or platelet disorder 
or abnormal coagulation test (PT/INR or PTT/aPTT greater than upper limit of 
normal) result at screening. 
10. Mechanical prosthetic heart valve surgery. 
11. Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory abnormality or other conditions or 
situations related to COVID-19 pandemic (eg, Contact with positive case, residence, 
or travel to an area with high incidence) that may increase the risk of study 
participation or, in the investigator’s judgment, make the participant inappropriate for 
the study.
Prior/Concomitant Therapy:
12. Use of prescription or nonprescription drugs and dietary and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study 
intervention. (Refer to Section 6.8 Concomitant Therapy for additional details).

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 40
13. Current use of any prohibited concomitant medication(s) or those unwilling/unable to 
use a permitted concomitant medication(s). Refer to Section 10.8 (Appendix 8) 
Concomitant Therapy.
14. Participants who have been vaccinated with COVID-19 vaccines within the past week 
(7 days) of dosing or are to be vaccinated with these vaccines at any time during the 
study confinement period.
Prior/Concurrent Clinical Study Experience:
15. Previous administration with an investigational drug within 30 days (or as determined 
by the local requirement) or 5 half-lives preceding the first dose of study intervention 
used in this study (whichever is longer). Participants who have participated in 
previous clinical trials with PF-07321332 may be eligible to participate in this study 
as long as they meet all other criteria. 
Diagnostic Assessments:
16. A positive urine drug test.
17. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at 
least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant’s eligibility.
18. Baseline 12-lead ECG (triplicate) that demonstrates clinically relevant abnormalities 
that may affect participant safety or interpretation of study results (eg, baseline QTcF 
interval >450 msec, complete LBBB, signs of an acute or indeterminate 
age- myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, 
second- or third-degree AV block, or serious bradyarrhythmias or tachyarrhythmias). 
If the baseline uncorrected QT interval is >450 msec, this interval should be rate 
corrected- using the Fridericia method and the resulting QTcF should be used for 
decision making and reporting. If QTcF exceeds 450 msec, or QRS exceeds 
120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or 
QRS values should be used to determine the participant’s eligibility. Computer
interpreted- ECGs should be overread by a physician experienced in reading ECGs 
before excluding a participant.  
19. Participants with ANY of the following abnormalities in clinical laboratory tests at 
screening, as assessed by the study specific- laboratory and confirmed by a single 
repeat test, if deemed necessary: 

AST or ALT level 1.0 × ULN;

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 41

Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert’s 
syndrome may have direct bilirubin measured and would be eligible for this study 
provided the direct bilirubin level is ≤ULN;

eGFR <90 mL/min/1.73m2 (-10%) based on the CKD-EPI equation.
Other Exclusions:
20. Active acute or chronic infection requiring treatment with oral/parenteral antibiotics, 
antivirals (including biologic treatments), antiparasitics, antiprotozoals, or 
antifungals.
21. Participants considered in imminent need for surgery or with elective surgery 
scheduled to occur during the study.
22. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 
5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit = 8 ounces [240 mL] beer, 
1 ounce [30 mL] of 40% spirit or 3 ounces [90 mL] of wine).
23. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or 
more within 60 days prior to dosing.
24. History of sensitivity to heparin or heparin–induced thrombocytopenia.
25. Unwilling or unable to comply with the criteria in the Lifestyle Considerations
section of this protocol.
26. Investigator site staff or Pfizer employees directly involved in the conduct of the 
study, site staff otherwise supervised by the investigator, and their respective family 
members. 
27. History of sensitivity reactions to ritonavir or dabigatran or any of the formulation 
components of PF-07321332, ritonavir, or dabigatran.
28. Women who are pregnant or breastfeeding or planning to become pregnant during the 
study period.
29. For any of the diagnostic tests/assessments, if a result is outside the normal limit, the 
principal investigator can make a decision in consult with the Pfizer medical monitor.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 42
5.3. Lifestyle Considerations
The following guidelines are provided:
5.3.1. Vaccine and Exposure to Infections Guidelines
Participant-Specific Recommendations:
It is recommended that all participants should be up-to-date with respect to standard of care 
vaccinations as defined by their country health ministry.
Guidance on Vaccinations:
Vaccination with live attenuated vaccine is prohibited within the 6 weeks prior to Day 1 
(Baseline), during the study, and until the last Follow up visit. Similarly, current routine 
household contact with individuals who have been vaccinated with live-attenuated vaccines 
should be avoided in the same period. This is due to the potential for virus to be shed in 
bodily fluids (including stool) following vaccination with live vaccines, leading to a potential 
risk that the virus may be transmitted. General guidelines for immunosuppressed subjects 
suggest that exposure (through routine contact) should be avoided following vaccination (of 
others) with these vaccines for the stated time period:
a.
Varicella or attenuated typhoid fever vaccination for 4 weeks following vaccination.
b. Oral polio vaccination for 6 weeks following vaccination.
c.
Attenuated rotavirus vaccine for 10 days following vaccination.
d. FluMist (intranasal flu vaccine) for 1 week following vaccination.
Participants should avoid exposure to vaccinated or infected persons and contact the 
investigator promptly if they develop signs or symptoms of any infections.
If a participant is offered, in accordance with the prevailing local guidelines, a non-live 
COVID-19 vaccine, it is permitted during this study and should be reported as a concomitant 
medication.
5.3.2. Meals and Dietary Restrictions

All study treatments, regardless of dosing regimen should be administered in the 
fasting condition (no food and drink except water). Specifically, morning doses 
should be followed by an overnight fast of approximately 8-10 hours. When PK is 
performed after the morning dose, a 4-hour fast should occur. Evening dose will be 
administered 1 hour before or 2 hours after a meal.

On days where no PK sampling is required, participants can resume normal intake of 
both food and water.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 43

Noncaffeinated drinks (except grapefruit or grapefruit related-citrus fruit juices—see 
below) may be consumed with meals and the evening snack.

Lunch can be provided approximately 4 hours after dosing the last dose of the 
morning of either dabigatran or PF-07321332/ritonavir. 

Dinner can be provided approximately 2 hours after dosing the last dose in the 
evening of either PF-07321332/ritonavir or ritonavir. 

An evening snack may be permitted.

Participants will refrain from consuming red wine, grapefruit, or grapefruit-related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from 7 days prior to the first 
dose of study intervention until collection of the final PK blood sample. 

While participants are confined, their total daily nutritional composition should be 
approximately 55% carbohydrate, 30% fat, and 15% protein. The daily caloric intake 
per participant should not exceed approximately 3200 kcal.
5.3.3. Caffeine, Alcohol, and Tobacco

Participants will abstain from caffeine containing products for 24 hours prior to the 
start of dosing until collection of the final PK sample of each study period. 

Participants will abstain from alcohol for 24 hours prior to admission (except as 
stated above for red wine) to the CRU and continue abstaining from alcohol until 
collection of the final PK sample of each study period. Participants may undergo an 
alcohol breath test or blood alcohol test at the discretion of the investigator.

Participants will abstain from the use of tobacco or nicotine containing products for 
24 hours prior to dosing and during confinement in the CRU. 
5.3.4. Activity

Participants will abstain from strenuous exercise (eg, heavy lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory tests. Walking at a normal pace will be permitted.
5.3.5. Contraception 
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4) and will confirm that the participant has been instructed in its 
consistent and correct use. At time points indicated in the schedule of activities (SoA), the 
investigator or designee will inform the participant of the need to use highly effective 
contraception consistently and correctly and document the conversation and the participant’s 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 44
affirmation in the participant’s chart (participants need to affirm their consistent and correct 
use of at least 1 of the selected methods of contraception) considering that their risk for 
pregnancy may have changed since the last visit. In addition, the investigator or designee will 
instruct the participant to call immediately if the selected contraception method is 
discontinued or if pregnancy is known or suspected in the participant or partner.
5.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently enrolled in the study. Screen failure data are collected and remain as 
source and are not reported on the CRF.
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened. 
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, medical device(s), or study procedure(s) intended to be administered to a study 
participant according to the study protocol.
For the purposes of this protocol, study intervention refers to PF-07321332/ritonavir and 
dabigatran.
6.1. Study Intervention(s) Administered
PF-07321332 100 mg tablets will be supplied by Pfizer. Ritonavir 100 mg tablets and 
dabigatran 75 mg capsules will be supplied by the CRU.
6.1.1. Administration
Investigational products will be administered orally and according to the conditions 
described in the SoA section and Protocol Section 5.3.2 Meals and Dietary Restrictions.
In T1, Day 1 participants will receive a single 75 mg dose of dabigatran administered orally
in the morning starting at approximately 0800 hours (plus or minus 2 hours). 
In T2, on Days 1 and 2, participants will receive 300 mg PF-07321332 administered orally 
with 100 mg ritonavir at approximately 0800 hours (plus or minus 2 hours). PF-07321332 
and ritonavir should be administered no more than 5 minutes of each other. PF-07321332 and 
ritonavir will be administered q12h on Days 1 (am and pm) and 2 (am only). On the morning 
of Day 2, a single oral dose of dabigatran 75 mg will be administered in combination with 
PF-07321332/ritonavir. Administration of dabigatran should occur at approximately 0815 to 
0830 hours (plus or minus 10 minutes) after administration of PF-07321332/ritonavir.
In T3, on Days 1 and 2, participants will receive 100 mg ritonavir q12h at approximately 
0800 hours (plus or minus 2 hours). Ritonavir will be administered q12h on Days 1 (am and 
pm) and 2 (am only). On the morning of Day 2, a single oral dose of 75 mg dabigatran will 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 45
be administered in combination with ritonavir. Administration of dabigatran should occur at 
approximately 0815 to 0830 hours (plus or minus 10 minutes) after administration of 
ritonavir. 
Each washout period will begin after the first dose of study treatment.
Investigator site personnel can administer water at ambient temperature in all Treatment 
periods. Study intervention will be administered according to the IMP and the protocol.
All study treatments, regardless of dosing regimen should be administered in the fasting 
condition (no food and drink except water). Specifically, morning doses should be followed 
by an overnight fast of approximately 8-10 hours. When PK is performed after the morning 
dose, a 4-hour fast should occur. Evening dose will be administered 1 hour before or 2 hours 
after a meal.  
6.2. Preparation, Handling, Storage, and Accountability
1.
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study interventions received and any 
discrepancies are reported and resolved before use of the study intervention. 
2.
Only participants enrolled in the study may receive study intervention and only 
authorized site staff may supply or administer study intervention. All study 
interventions must be stored in a secure, environmentally controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking days must 
indicate the minimum and maximum temperatures since previously documented for 
all site storage locations upon return to business.
3.
Any excursions from the study intervention label storage conditions should be 
reported to Pfizer upon discovery along with any actions taken. The site should 
actively pursue options for returning the study intervention to the storage conditions 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study intervention must be quarantined and not used until Pfizer provides permission 
to use the study intervention. Specific details regarding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the IP manual.
4.
Any storage conditions stated in the SRSD will be superseded by the storage 
conditions stated on the label.
5.
Study interventions should be stored in their original containers.
6.
The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for study intervention accountability, reconciliation, and record 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 46
maintenance (ie, receipt, reconciliation, and final disposition records), such as the 
IPAL or sponsor-approved equivalent. All study interventions will be accounted for 
using a study intervention accountability form/record.
7.
Further guidance and information for the final disposition of unused study 
interventions are provided in the IP manual. All destruction must be adequately 
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroyed in compliance with 
applicable environmental regulations, institutional policy, and any special 
instructions provided by Pfizer.
Upon identification of a product complaint, notify the sponsor within 1 business day of 
discovery as described in the IP manual.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study intervention ready for administration or dispensing to the participant by qualified 
staff. Dispensing is defined as the provision of study intervention, concomitant treatments, 
and accompanying information by qualified staff member(s) to a healthcare provider, 
participant in accordance with this protocol. Local health authority regulations or investigator 
site guidelines may use alternative terms for these activities.
The tablets/capsules will be provided in unit dose containers and labeled in accordance with 
Pfizer regulations and the clinical site’s labeling requirements. 
Study intervention should be prepared and dispensed by an appropriately qualified and 
experienced member of the study staff (eg, physician, nurse, physician’s assistant, nurse 
practitioner, pharmacy assistant/technician, or pharmacist) as allowed by local, state, and 
institutional guidance. A second staff member will verify the dispensing.
6.3. Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study Intervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participants are enrolled.
The investigator will assign participant numbers to the participants as they are screened for 
the study. All participants enrolled will receive treatment according to the dose/schedule.
6.4. Study Intervention Compliance
When participants are dosed at the site, they will receive study intervention directly from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF. 
The dose of study intervention and study participant identification will be confirmed at the 
time of dosing by a member of the study site staff other than the person administering the 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 47
study intervention. Study site personnel will examine each participant’s mouth to ensure that 
the study intervention was ingested.
6.5. Dose Modification 
No dose modification is anticipated.
6.6. Continued Access to Study Intervention After the End of the Study
No intervention will be provided to study participants at the end of their study participation.
6.7. Treatment of Overdose
For this study, any dose of PF-07321332 greater than 600 mg or ritonavir greater than 
200 mg within a 24-hour time period (2 hours) will be considered an overdose.
An accidental overdose of dabigatran may lead to hemorrhagic complications. In the event of 
hemorrhagic complications, initiate appropriate clinical support, discontinue treatment, and 
investigate the source of bleeding. For dabigatran, a specific reversal agent (idarucizumab) is 
available.9
There is no specific treatment for an overdose of either PF-07321332 or ritonavir.  
In the event of an overdose, the investigator should:
1. Contact the Pfizer medical monitor within 24 hours.
2. Closely monitor the participant for any AEs/SAEs and laboratory abnormalities for at 
least 5 half-lives or 28 calendar days after the overdose of PF-07321332 or ritonavir 
(whichever is longer).
3. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.
4. Overdose is reportable to Pfizer Safety only when associated with an SAE.
5. Obtain a blood sample for PK analysis within 1 days from the date of the last dose of 
study intervention if requested by the medical monitor (determined on a case-by-case 
basis).
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the medical monitor based on the clinical evaluation of the participant.
6.8. Concomitant Therapy
Use of prescription or nonprescription drugs and dietary and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study 
intervention. Limited use of nonprescription medications that are not believed to affect 
participant safety or the overall results of the study may be permitted on a case-by-case basis 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 48
following approval by the sponsor. Acetaminophen/paracetamol may be used at doses 
of ≤1 g/day.
Herbal supplements and hormonal methods of contraception (including oral and transdermal 
contraceptives, injectable progesterone, vaginal ring, and postcoital contraceptive methods)
and hormone replacement therapy must have been discontinued at least 28 days prior to the 
first dose of investigational product.
All concomitant treatments taken during the study must be recorded with indication, daily 
dose, and start and stop dates of administration. All participants will be questioned about 
concomitant treatment at each clinic visit.
Treatments taken within 28 days before the first dose of study intervention will be 
documented as a prior treatment. Treatments taken after the first dose of study intervention 
will be documented as concomitant treatments.
6.8.1. Rescue Medicine 
There is no rescue therapy to reverse the AEs observed with PF-07321332 or ritonavir. For 
dabigatran, the specific reversal agent (idarucizumab) is available.9 Standard medical 
supportive care must be provided to manage the AEs. 
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study Intervention
It may be necessary for a participant to permanently discontinue study intervention. Reasons 
for permanent discontinuation of study intervention include the following: 

AE requiring discontinuation in investigator’s view,

Pregnancy,

Positive COVID-19 test.
If a positive COVID-19 test is confirmed during study conduct, and if in the opinion of the
Principal Investigator, in consultation with the sponsor, it is in the best interest of either the 
participant or the investigational site to discontinue, then the participant should be 
discontinued from the study. 
If study intervention is permanently discontinued, the participant will not remain in the study 
for further evaluation. See the SoA for data to be collected at the time of discontinuation of 
study intervention.
In the event of discontinuation of study intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 49
receipt of study intervention or also from study procedures, posttreatment study follow-up, 
and/or future collection of additional information.
If a participant uses prohibited medication, guidance in Appendix 8 should be followed.  
7.1.1. ECG Changes
A participant who meets either bulleted criterion based on the average of triplicate ECG 
readings will be withdrawn from the study intervention. 

QTcF >500 msec.

Change from baseline: QTcF >60 msec and QTcF >450 msec.
If a clinically significant finding is identified (including, but not limited to, changes from 
baseline in QTcF after enrollment), the investigator or qualified designee will determine if 
the participant can continue in the study and if any change in participant management is 
needed. This review of the ECG printed at the time of collection must be documented. Any 
new clinically relevant finding should be reported as an AE.
7.1.2. Potential Cases of Acute Kidney Injury
Abnormal values in SCr concurrent with presence or absence of increase in BUN that meet 
the criteria below, in the absence of other causes of kidney injury, are considered potential 
cases of acute kidney injury and should be considered important medical events. 
An increase of ≥0.3 mg/dL (or ≥26.5 µmol/L) in SCr level relative to the participant’s own 
baseline measurement should trigger another assessment of SCr as soon as practically 
feasible, preferably within 48 hours from awareness.
If the second assessment (after the first observations of ≥0.3 mg/dL [or ≥26.5 µmol/L] in SCr 
relative to the participant’s own baseline measurement) is ≥0.4 mg/dL (or ≥35.4 µmol/L), the 
participant should be discontinued from the study and adequate, immediate, supportive 
measures taken to correct apparent acute kidney injury.
Participants should return to the investigator site and be evaluated as soon as possible, 
preferably within 48 hours from awareness of the second assessment confirming abnormal 
SCr result. This evaluation should include laboratory tests, detailed history, and physical 
assessment. In addition to repeating SCr, laboratory tests should include serum BUN, serum 
creatine kinase, and serum electrolytes (including at a minimum potassium, sodium, 
phosphate/phosphorus, and calcium), in addition to urinary dipstick, urine microscopic 
examination, and urinary indices. All cases confirmed on repeat testing as meeting the 
laboratory criteria for acute kidney injury, with no other cause(s) of laboratory abnormalities 
identified, should be considered potential cases of drug-induced kidney injury irrespective of 
availability of all the results of the investigations performed to determine etiology of the 
abnormal SCr. If ≥2 healthy participants are noted to have 2 consecutive SCr results of 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 50
≥0.3 mg/dL (or ≥26.5 µmol/L), an assessment of whether the finding may be considered an 
adverse drug reaction should be undertaken.
7.1.3. Liver Injury
Reasons for permanent discontinuation of study intervention due to potential liver injury are 
described in Appendix 6.
7.2. Participant Discontinuation/Withdrawal From the Study 
A participant may withdraw from the study at any time at his/her own request. Reasons for 
discontinuation from the study include the following:

Refused further study procedures;

Lost to follow-up;

Death;

Study terminated by sponsor;

Investigator decision.
At the time of discontinuing from the study, if possible, an early discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study 
discontinuation and follow-up and for any further evaluations that need to be completed. 
The early discontinuation visit applies only to participants who are enrolled/randomized and 
then are prematurely withdrawn from the study. Participants should be questioned regarding 
their reason for withdrawal. 
If a participant withdraws from the study, he/she may request destruction of any remaining 
samples taken and not tested, and the investigator must document any such requests in the 
site study records and notify the sponsor accordingly.
If the participant withdraws from the study and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may retain and continue to use any data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participants who request to discontinue receipt of study intervention will remain in the study 
and must continue to be followed for protocol specified follow-up procedures. The only 
exception to this is when a participant specifically withdraws consent for any further contact 
with him or her or persons previously authorized by the participant to provide this 
information. Participants should notify the investigator in writing of the decision to withdraw 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 51
consent from future follow-up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records by the investigator, as to whether the withdrawal is 
only from further receipt of study intervention or also from study procedures and/or 
posttreatment study follow-up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly available 
information should be used to determine vital status only as appropriately directed in 
accordance with local law.
7.3. Lost to Follow-Up 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:

The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible. Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the study.

Before a participant is deemed lost to follow-up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record.

Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8. STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any study specific procedures. 
Study procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety issues should be discussed with the sponsor immediately upon occurrence or 
awareness to determine whether the participant should continue or discontinue study 
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 52
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study intervention 
to confirm that they meet the study population criteria for the study. If the time between 
screening and dosing exceeds 28 days as a result of unexpected delays (eg, delayed drug 
shipment), then participants do not require rescreening if the laboratory results obtained prior 
to first dose administration meet eligibility criteria.
Every effort should be made to ensure that protocol required- tests and procedures are 
completed as described. However, it is anticipated that from time to time there may be 
circumstances outside the control of the investigator that may make it unfeasible to perform 
the test. In these cases, the investigator must take all steps necessary to ensure the safety and 
well-being of the participant. When a protocol required test cannot be performed, the 
investigator will document the reason for the missed test and any corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study team must be informed of these incidents in a timely manner.
If an IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion of the catheter.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study.
The total blood sampling volume for individual participants in this study is approximately 
470 mL. The actual collection times of blood sampling may change. Additional blood 
samples may be taken for safety assessments at times specified by Pfizer, provided the total 
volume taken during the study does not exceed 550 mL during any period of 60 consecutive 
days.
To prepare for study participation, participants will be instructed on the information in 
Protocol Section 5.3 Lifestyle Considerations and Section 6.8 Concomitant Therapy.
8.1. Efficacy Assessments
Not applicable.
8.2. Safety Assessments
Planned time points for all safety assessments are provided in the SoA. Unscheduled clinical 
laboratory measurements may be obtained at any time during the study to assess any 
perceived safety issues.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 53
8.2.1. Physical Examinations
A complete PE will include, at a minimum, head, ears, eyes, nose, mouth, skin, heart and 
lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological 
systems. A medical history will also be collected including smoking status and alcohol use.
A brief PE will include, at a minimum, assessments of general appearance, the respiratory 
and cardiovascular systems, and participant reported symptoms. 
PEs may be conducted by a physician, trained physician’s assistant, or nurse practitioner as 
acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. Participants must remove shoes, bulky layers of clothing, and jackets so that only 
light clothing remains. They must also remove the contents of their pockets and remain still 
during measurement of weight. 
PE findings collected during the study will be considered source data and will not be required 
to be reported, unless otherwise noted. Any untoward PE findings that are identified during 
the active collection period and meet the definition of an AE or SAE (Appendix 3) must be 
reported according to the processes in Section 8.3.1 to Section 8.3.3.
8.2.2. Vital Signs
Supine BP will be measured with the participant’s arm supported at the level of the heart and 
recorded to the nearest mm Hg after approximately 5 minutes of rest. The same arm 
(preferably the dominant arm) will be used throughout the study. Participants should be 
instructed not to speak during measurements. 
The same properly sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manually, pulse rate will be measured in the brachial/radial artery for at least 
30 seconds. When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection. 
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety data.
8.2.2.1. Respiratory Rate 
Respiratory rate will be measured after approximately 5 minutes of rest in a supine position 
by observing and counting the respirations of the participant for 30 seconds and multiplying 
by 2. When BP is to be taken at the same time, respiration measurement will be done during 
the 5 minutes of rest and before BP measurement.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 54
8.2.2.2. Temperature
Temperature will be measured orally (other body locations, eg, tympanic, are acceptable 
provided the same method is used and documented throughout the study). No eating, 
drinking, or smoking is allowed for 15 minutes prior to the measurement.
8.2.3. Electrocardiograms
Standard 12-lead ECGs utilizing limb leads (with a 10 second rhythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex. Alternative lead placement methodology using torso leads (eg, Mason-Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant 
has rested quietly for approximately 10 minutes in a supine position. 
Triplicate 12-lead ECGs will be obtained approximately 2 to 4 minutes apart; the average of 
the triplicate ECG measurements collected before dose administration on Day 1 of each 
period will serve as each participant’s baseline QTc value.
To ensure safety of the participants, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
post-dose QTcF interval is increased by ≥60 msec from the baseline and is >450 msec for 
participants with normal renal function and >470 msec for participants with impaired renal 
function; or b) an absolute QT value is ≥500 msec for any scheduled ECG. If either of these 
conditions occurs, then 2 additional ECGs will be collected approximately 2 to 4 minutes 
apart to confirm the original measurement. If the QTc values from these repeated ECGs 
remain above the threshold value, then a single ECG must be repeated at least hourly until 
QTc values from 2 successive ECGs fall below the threshold value that triggered the repeat 
measurement.
If a) a postdose QTcF interval remains ≥60 msec from the baseline and is >450 msec for 
participants with normal renal function and >470 msec for participants with impaired renal 
function; or b) an absolute QT value is ≥500 msec for any scheduled ECG for greater than 
4 hours (or sooner, at the discretion of the investigator); or c) QTcF intervals get 
progressively longer, the participant should undergo continuous ECG monitoring. A 
cardiologist should be consulted if QTcF intervals do not return to less than the criteria listed 
above after 8 hours of monitoring (or sooner, at the discretion of the investigator). 
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads be placed in the 
same positions each time in order to achieve precise ECG recordings. If a machine read- QTc 
value is prolonged, as defined above, repeat measurements may not be necessary if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern are listed in Appendix 7.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 55
8.2.4. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safety laboratory tests to be performed and the SoA for 
the timing and frequency. All protocol required laboratory assessments, as defined in 
Appendix 2, must be conducted in accordance with the laboratory manual and the SoA. 
Unscheduled clinical laboratory measurements may be obtained at any time during the study 
to assess any perceived safety issues. 
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF. 
Clinically significant abnormal laboratory findings are those which are not associated with 
the underlying disease, unless judged by the investigator to be more severe than expected for 
the participant’s condition.
All laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within 48 hours after the last dose of study intervention should 
be repeated until the values return to normal or baseline or are no longer considered clinically 
significant by the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by 
the investigator, the etiology should be identified and the sponsor notified.
For any of the clinical safety laboratory assessments, if a result is outside the normal limit, 
the principal investigator in consult with the Pfizer medical monitor can make a decision 
regarding clinical significance. 
See Appendix 6 for suggested actions and follow-up assessments in the event of potential 
drug-induced liver injury.
Urine drug (mandatory) and alcohol breath test (at discretion of investigator) will be
performed at Screening and on Day -1. These tests may be performed at any other time at the 
discretion of the investigator.
8.2.5. COVID-19 Specific Assessments 
Participants will be tested for SARS-COV-2 infection by RT-PCR prior to being admitted to 
the clinic for confinement and a subsequent SARS-CoV-2 test or rapid testing assessment 
(eg, Abbot) will be performed after 4 days (ie, upon completion of 4 × 24 hours in house), or 
if they develop COVID-19 like symptoms. Additional testing may be required by local 
regulations or by the Principal Investigator.
8.2.6. Pregnancy Testing 
Pregnancy tests may be urine or serum tests, but must have a sensitivity of at least 
25 mIU/mL. Pregnancy tests will be performed in WOCBP at the times listed in the SoA. 
Following a negative pregnancy test result at screening, appropriate contraception must be 
commenced and a second negative pregnancy test result will be required at the baseline visit 
prior the participant’s receiving the study intervention. Pregnancy tests will also be done 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 56
whenever 1 menstrual cycle is missed during the active treatment period (or when potential 
pregnancy is otherwise suspected) and at the end of the study. Pregnancy tests may also be 
repeated if requested by IRBs/ECs or if required by local regulations. If a urine test cannot be 
confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such 
cases, the participant must be excluded if the serum pregnancy result is positive.
The pregnancy test outcome should be documented in the participant’s source 
documents/medical records and relevant data recorded on the CRF. The investigator, or his 
or her designee, will confirm that the participant is adhering to the contraception method(s) 
required in the protocol. The required frequency of pregnancy testing for this study is 
described in the SoA.
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3.
AEs may arise from symptoms or other complaints reported to the investigator by the 
participant (or, when appropriate, by a caregiver, surrogate, or the participant’s legally 
authorized representative), or they may arise from clinical findings of the investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study intervention (see Section 7.1). 
During the active collection period as described in Section 8.3.1, each participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may be requested by Pfizer Safety to obtain specific follow-up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant’s participation in the study (ie, before undergoing 
any study related procedure and/or receiving study intervention), through and including a 
minimum of 28 calendar days, except as indicated below, after the last administration of the 
study intervention.
Follow-up by the investigator continues throughout and after the active collection period and 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 57
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently discontinues or temporarily discontinues study intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to actively seek information on AEs or SAEs after the 
participant has concluded study participation. However, if the investigator learns of any SAE, 
including a death, at any time after a participant has completed the study, and he/she 
considers the event to be reasonably related to the study intervention, the investigator must 
promptly report the SAE to Pfizer using the CT SAE Report Form.
8.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.1 are reported to Pfizer Safety on the CT SAE Report Form immediately upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any updated SAE data to the sponsor within 
24 hours of it being available.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.1, will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly observed, and all spontaneously reported 
AEs and SAEs reported by the participant.
Reporting of AEs and SAEs for participants who fail screening are subject to the CRF 
requirements as described in Section 5.4.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 58
8.3.3. Follow-up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow-up (as defined in Section 7.3).
In general, follow-up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality. Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary of available 
autopsy findings must be submitted as soon as possible to Pfizer Safety. 
Further information on follow-up procedures is given in Appendix 3.
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities toward the safety of participants and the safety of 
a study intervention under clinical investigation are met.
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
sponsor will comply with country-specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRBs/ECs, and investigators.
Investigator safety reports must be prepared for SUSARs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.
An investigator who receives SUSARs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact with or exposure to the study intervention. Such exposure 
may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, family members, and others who may be exposed. 
An environmental exposure may include exposure during pregnancy, exposure during 
breastfeeding, and occupational exposure.
Any such exposure to the study intervention under study are reportable to Pfizer Safety 
within 24 hours of investigator awareness.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 59
8.3.5.1. Exposure During Pregnancy
An EDP occurs if: 

A female participant is found to be pregnant while receiving or after discontinuing 
study intervention.

A male participant who is receiving or has discontinued study intervention exposes 
a female partner prior to or around the time of conception. 

A female is found to be pregnant while being exposed or having been exposed to 
study intervention due to environmental exposure. Below are examples of 
environmental EDP: 

A female family member or healthcare provider reports that she is pregnant after 
having been exposed to the study intervention by ingestion, inhalation or skin 
contact.

A male family member or healthcare provider who has been exposed to the study 
intervention by ingestion, inhalation or skin contact then exposes his female 
partner prior to or around the time of conception. 
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy). 

If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to Pfizer Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy will be collected after the start of study intervention and until 28 days after 
the last dose. 

If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study, the information is not recorded on a CRF; however, a copy of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow-up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy until 
completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as 
a follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrity of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically possible, the structural 
integrity of the terminated fetus should be assessed by gross visual inspection (unless 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 60
preprocedure test findings are conclusive for a congenital anomaly and the findings are 
reported).
Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomaly in a liveborn baby, a terminated fetus, 
an intrauterine fetal demise, or a neonatal death), the investigator should follow the 
procedures for reporting SAEs. Additional information about pregnancy outcomes that are 
reported to Pfizer Safety as SAEs follows: 

Spontaneous abortion including miscarriage and missed abortion.

Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly related to 
exposure to the study intervention. 
Additional information regarding the EDP may be requested by the sponsor. Further 
follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on 
preterm infants to identify developmental delays). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 

A female participant is found to be breastfeeding while receiving or after 
discontinuing study intervention.

A female is found to be breastfeeding while being exposed or having been exposed to 
study intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study intervention 
by ingestion, inhalation, or skin contact. 
The investigator must report exposure during breastfeeding to Pfizer Safety within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study, so the information is not recorded on 
a CRF. However, a copy of the completed CT SAE Report Form is maintained in the 
investigator site file.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 61
An exposure during breastfeeding report is not created when a Pfizer drug specifically 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
8.3.5.3. Occupational Exposure
The investigator must report any instance of occupational exposure to Pfizer Safety within 
24 hours of the investigator’s awareness using the CT SAE Report Form regardless of 
whether there is an associated SAE. Since the information about the occupational exposure 
does not pertain to a participant enrolled in the study, the information is not recorded on 
a CRF; however, a copy of the completed CT SAE Report Form must be maintained in the 
investigator site file.
8.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease Related-Events and/or Disease Related- Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
AESIs are examined as part of routine safety data review procedures throughout the clinical 
trial and as part of signal detection processes.
All AESIs must be reported as an AE or SAE following the procedures described in 
Section 8.3.1 through 8.3.4. An AESI is to be recorded as an AE or SAE on the CRF. In 
addition, an AESI that is also an SAE must be reported using the CT SAE Report Form.
8.3.8.1. Lack of Efficacy
This section is not applicable because efficacy is not expected in the study population.
8.3.9. Medical Device Deficiencies
Not applicable.
8.3.10. Medication Errors
Medication errors may result from the administration or consumption of the study 
intervention by the wrong participant, or at the wrong time, or at the wrong dosage strength.
Exposures to the study intervention under study may occur in clinical trial settings, such as 
medication errors.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 62
Safety Event
Recorded on the CRF
Reported on the CT SAE Report 
Form to Pfizer Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)
Only if associated with an SAE
Medication errors include:
•
Medication errors involving participant exposure to the study intervention.
•
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant.
For further clarification, a medication error is:
•
Any preventable event causing or leading to inappropriate medication use or 
participant harm;
•
When a participant misunderstood, could not read, was not aware of, or not given 
dosing instructions
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours.
Whether or not the medication error is accompanied by an AE, as determined by the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the 
CRF. 
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.4. Pharmacokinetics 
8.4.1. Plasma for Analysis of PF-07321332, Ritonavir, and Dabigatran
Blood samples of approximately 4 mL, to provide a minimum of 1.5 mL of plasma will be 
collected for measurement concentrations of dabigatran (total), PF-07321332 and ritonavir as 
specified in the SoA.
 
 
Instructions for the collection 
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 63
and handling of biological samples will be provided in the laboratory manual or by the 
sponsor. The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of 
samples up to and including 10 hours after dose administration that are obtained within 
10% of the nominal time relative to dosing (eg, within 6 minutes of a 60 minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and the CRF. Collection of samples more than 10 hours after dose
administration that are obtained ≤1 hour away from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and the CRF. 
 
 
 
 
Genetic analyses will not be performed on these plasma samples unless consent for this was 
included in the informed consent. Participant confidentiality will be maintained.
 
 
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shipping 
conditions), including any actions taken, must be documented and reported to the sponsor. 
On a case-by-case basis, the sponsor may make a determination as to whether sample 
integrity has been compromised.
 
 
 
CCI
CCI
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 64
 
 
 
 
 
8.7. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.8. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in the SAP, which will be maintained by the sponsor. 
The SAP may modify what is outlined in the protocol where appropriate; however, any major 
modifications of the primary endpoint definitions or their analyses will also be reflected in a 
protocol amendment.
9.1. Statistical Hypotheses
No statistical hypothesis will be tested in this study.
9.2. Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Participant Analysis Set
Description
PK Concentration
The PK concentration population is defined as all 
participants assigned to investigational product and 
treated who have at least 1 concentration measured.
CCI
CCI
CCI
CCI
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 65
Participant Analysis Set
Description
PK Parameter
The PK parameter analysis population is defined as all 
participants assigned to investigational product and 
treated who have at least 1 of the PK parameters of 
primary interest measured.
Safety Analysis Set
All participants randomly assigned to study intervention 
and who take at least 1 dose of study intervention. 
Participants will be analyzed according to the product 
they actually received.
9.3. Statistical Analyses
The SAP will be developed and finalized before any analyses are performed and will 
describe the analyses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analyses of the primary and secondary 
endpoints.
9.3.1. Pharmacokinetic Analyses
9.3.1.1. Derivation of Pharmacokinetic Parameters Prior to Analysis
The plasma PK parameters for PF-07321332, ritonavir, and dabigatran (total) will be derived 
from the concentration time profiles as detailed in Table 1 for each analyte and treatment. 
Actual PK sampling times will be used in the derivation of PK parameters. In the case that 
actual PK sampling times are not available, nominal PK sampling time will be used in the 
derivation of PK parameters.
Table 1.
Plasma PK Parameters
Parameter
Analyte
Definition
Method of Determination
AUClast
dabigatran
Area under the plasma 
concentration-time profile 
from time 0 to the time of 
the last quantifiable 
concentration (Clast)
Linear/Log trapezoidal method.
AUCinf
dabigatran
Area under the plasma 
concentration-time profile 
from time 0 extrapolated to 
infinite time
AUClast + (Clast*/kel), Where Clast* is 
the predicted plasma concentration 
at the last quantifiable time point 
estimated from the log-linear 
regression analysis.
AUCtau
PF-07321332 and 
ritonavir
Area under the plasma 
concentration-time profile 
from time 0 to time tau (τ) 
the dosing interval, where 
tau=12 hours for BID 
dosing.
Linear/Log trapezoidal method.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 66
Table 1.
Plasma PK Parameters
Parameter
Analyte
Definition
Method of Determination
Cmax
PF-07321332, ritonavir, 
dabigatran
Maximum plasma 
concentration
Observed directly from data.
Tmax
PF-07321332, ritonavir, 
dabigatran
Time for Cmax
Observed directly from data as time 
of first occurrence.
t½a
PF-07321332, ritonavir, 
dabigatran
Terminal elimination 
half-life
Loge(2)/kel, where kel is the terminal 
phase rate constant calculated by a 
linear regression of the log-linear 
concentration-time curve. Only 
those data points judged to describe 
the terminal log-linear decline will 
be used in the regression.
CL/Fa
PF-07321332, ritonavir, 
dabigatran
Apparent clearance
Dabigatran (SD): Dose/AUCinf
PF-07321332 and ritonavir (MD): 
Dose/AUCtau
Vz/Fa
PF-07321332, ritonavir, 
dabigatran
Apparent volume of 
distribution
Dabigatran (SD): Dose/(AUCinf•kel)
PF-07321332 and ritonavir (MD): 
Dose/(AUCtau•kel)
a.
If data permit.
9.3.2. Statistical Methods for PK Data
The plasma concentrations of PF-07321332, ritonavir and dabigatran will be listed and 
descriptively summarized by nominal PK sampling time and treatment. Individual 
participant, as well as mean and median profiles of the plasma concentration time data will 
be plotted by treatment for each analyte using actual (for individual) and nominal (for mean 
and median) times respectively. Mean and median profiles will be presented on both linear 
and semi-log scales. For comparison of AUCinf and Cmax with and without dabigatran, box 
and whisker plots of these parameters will be plotted by treatment for each analyte. 
Natural log transformed parameters (AUCinf [if data permit)], AUClast, and Cmax) of 
dabigatran will be analyzed using a mixed effect model with treatment, period and sequence 
as fixed effects and participant within sequence as a random effect. Estimates of the adjusted 
mean differences (Test-Reference) and corresponding 90% CIs will be obtained from the 
model. The adjusted mean differences and 90% CIs for the differences will be exponentiated 
to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CI 
for the ratios. Dabigatran administered alone will be the reference treatment and 
PF-07321332/ritonavir co-administered with dabigatran and ritonavir co-administered with 
dabigatran will be the test treatments.
Additional specifications about the tables, listings, and figures will be outlined in the SAP.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 67
9.3.3. Other Safety Analyses
All safety analyses will be performed on the safety population.
AEs, ECGs, vital signs (BP, pulse rate, RR and temperature) and safety laboratory data will 
be reviewed and summarized on an ongoing basis during the study to evaluate the safety of 
participants. Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential 
clinical concern will be described. Safety data will be presented in tabular and/or graphical 
format and summarized descriptively, where appropriate.
Medical history and PE and neurological examination information, as applicable, collected 
during the course of the study will be considered source data and will not be required to be 
reported, unless otherwise noted. However, any untoward findings identified on physical 
and/or neurological examinations conducted during the active collection period will be 
captured as AEs, if those findings meet the definition of an AE. Data collected at screening 
that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, 
will be considered source data, and will not be required to be reported, unless otherwise 
noted. Demographic data collected at screening will be reported.
All safety analyses will be summarized in accordance with Pfizer implemented CDISC 
Standards. All participants who receive IP (safety population) will be included in the safety 
analyses. All safety data will be summarized descriptively through appropriate data 
tabulations, descriptive statistics, categorical summaries, and graphical presentations.
The incidence of the primary safety endpoints of TEAEs and SAEs, as well as SAEs and AEs 
leading to discontinuation will be summarized for each dose group.
 
 
9.4. Interim Analyses
No formal interim analysis will be conducted for this study. As this is an open-label study, 
the sponsor may conduct unblinded reviews of the data during the course of the study for the 
purpose of safety assessment, facilitating PK/PD modeling, and/or supporting clinical 
development.
9.5. Sample Size Determination
A sample size of approximately 24 participants will provide adequate precision to estimate 
the effects of multiple dose PF-07321332/ritonavir on the PK of single dose dabigatran. The 
expected widths of the 90% CIs with 80% coverage probability are shown in the following 
table for a range of possible effects. 
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 68
Parameter
Estimated Effect 
(100*Test/Reference)
90% CI
CI Width
AUCinf
80%
100%
120%
140%
160%
180%
63.09%, 101.45%
78.86%, 126.81%
94.63%, 152.17%
110.40%, 177.53%
126.17%, 202.89%
141.95%, 228.26%
38.36%
47.95%
57.54%
67.13%
76.72%
86.31%
Cmax
80%
100%
120%
140%
160%
180%
60.49%, 105.80%
75.61%, 132.25%
90.74%, 158.70%
105.86%, 185.15%
120.98%, 211.60%
136.10%, 238.06%
45.31%
56.64%
67.97%
79.30%
90.62%
101.95%
These estimates are based on the assumption that within-participant standard deviations are 
0.452 and 0.532 for lnAUCinf and lnCmax, respectively, as obtained from the mean of 2 
clinical studies (B1871043 and B7451026) and literature4 in healthy participants.
Participants who withdraw from the study may be replaced at the discretion of the Principal 
investigator upon consultation with the sponsor.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 69
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study will be conducted in accordance with the protocol and with the following:

Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;

Applicable ICH GCP guidelines;

Applicable laws and regulations, including applicable privacy laws.
The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents 
(eg, advertisements) must be reviewed and approved by the sponsor, submitted to an IRB/EC 
by the investigator, and reviewed and approved by the IRB/EC before the study is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.
Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study participants.
The investigator will be responsible for the following:

Providing written summaries of the status of the study to the IRB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/EC;

Notifying the IRB/EC of SAEs or other significant safety findings as required by 
IRB/EC procedures;

Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the IRB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations.
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable 
regulatory authority in any area of the world, or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, Pfizer should be informed immediately. 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 70
In addition, the investigator will inform Pfizer immediately of any urgent safety measures 
taken by the investigator to protect the study participants against any immediate hazard, and 
of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Informed Consent Process
The investigator or his/her representative will explain the nature of the study, including the 
risks and benefits, to the participant and answer all questions regarding the study. The 
participant should be given sufficient time and opportunity to ask questions and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy and data protection requirements, where 
applicable, and the IRB/EC or study center.
The investigator must ensure that each study participant is fully informed about the nature 
and objectives of the study, the sharing of data related to the study, and possible risks 
associated with participation, including the risks associated with the processing of the 
participant’s personal data. 
The participant must be informed that his/her personal study related-data will be used by the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/EC members, and by inspectors from regulatory authorities.
The investigator further must ensure that each study participant is fully informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date on which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study.
A copy of the ICD(s) must be provided to the participant.
Participants who are rescreened are required to sign a new ICD.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 71
10.1.3. Data Protection
All parties will comply with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study site in encrypted electronic form and/or 
paper and will be password-protected or secured in a locked room to ensure that only 
authorized study staff have access. The study site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by law.
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant specific- numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by this single, participant specific- code. The study site will 
maintain a confidential list of participants who participated in the study, linking each 
participant’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality of participants’ personal data 
consistent with the clinical study agreement and applicable privacy laws.
10.1.4. Committees Structure
10.1.4.1. Data Monitoring Committee 
This study will not use a DMC.
10.1.5. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, Pfizer reports study results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study or the country in 
which the study was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer-sponsored interventional 
studies (conducted in patients) that evaluate the safety and/or efficacy of a product, 
regardless of the geographical location in which the study is conducted. These results are 
submitted for posting in accordance with the format and timelines set forth by US law.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 72
EudraCT
Pfizer posts clinical trial results on EudraCT for Pfizer-sponsored interventional studies in 
accordance with the format and timelines set forth by EU requirements.
www.pfizer.com
Pfizer posts public disclosure synopses (CSR synopses in which any data that could be used 
to identify individual participants have been removed) on www.pfizer.com for Pfizer 
sponsored interventional studies at the same time the corresponding study results are posted 
to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy 0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy, includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this 
policy, includes the publishing of individual participant data. Policy 0070 applies to new 
marketing authorization applications submitted via the centralized procedure since 
01 January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July 2015.
Data sharing
Pfizer provides researchers secure access to patient-level data or full CSRs for the purposes 
of “bona-fide scientific research” that contributes to the scientific understanding of the 
disease, target, or compound class. Pfizer will make data from these trials available 
24 months after study completion. Participant level- data will be anonymized in accordance 
with applicable privacy laws and regulations. CSRs will have personally identifiable 
information redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is 
responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the CRF.
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 73
The investigator must ensure that the CRFs are securely stored at the study site in encrypted 
electronic and/or paper form and are password-protected or secured in a locked room to 
prevent access by unauthorized third parties.
QTLs are predefined parameters that are monitored during the study. Important deviations 
from the QTLs and any remedial actions taken will be summarized in the clinical study 
report.
The investigator must permit study related- monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source data documents. This 
verification may also occur after study completion. It is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy, including definition of study critical data items and 
processes (eg, risk based- initiatives in operations and quality, such as risk management and 
mitigation strategies and analytical risk based- monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on-site monitoring), are provided in the data management plan and IQMP 
maintained and utilized by the sponsor or designee.
The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained by the investigator for 15 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the sponsor. No records may be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securely for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly and irrevocably deleted from all systems.
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly resolve any discrepancies that are identified
between the study data and the participant’s medical records. The investigator will promptly 
provide copies of the inspection findings to the sponsor or its agent. Before response 
submission to the regulatory authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to any such findings.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 74
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, depending on 
the study. Also, current medical records must be available.
Definition of what constitutes source data and its origin can be found in the Source 
Document Locator, which is maintained by the sponsor.
Description of the use of the computerized system is documented in the Source Document 
Locator, which is maintained by the sponsor.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP guidelines, and all applicable regulatory requirements.
10.1.8. Study and Site Start and Closure
The study start date is the date on which the clinical study will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study 
start date.
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study site- closure visit has been performed.
The investigator may initiate study-site closure at any time upon notification to the sponsor if 
requested to do so by the responsible IRB/EC or if such termination is required to protect the 
health of study participants.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 75
Reasons for the early closure of a study site by the sponsor may include but are not limited 
to:

Failure of the investigator to comply with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor’s procedures, or the ICH GCP 
guidelines;

Inadequate recruitment of participants by the investigator;

Discontinuation of further study intervention development.
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IRB/ECs, the regulatory authorities, and any CRO(s) used in the study of 
the reason for termination or suspension, as specified by the applicable regulatory 
requirements. The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow-up.
Study termination is also provided for in the clinical study agreement. If there is any conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study may be published or presented at scientific meetings by the 
investigator after publication of the overall study results or 1 year after the end of the study 
(or study termination), whichever comes first. 
The investigator agrees to refer to the primary publication in any subsequent publications, 
such as secondary manuscripts, and submits all manuscripts or abstracts to the sponsor 
30 days before submission. This allows the sponsor to protect proprietary information and to 
provide comments, and the investigator will, on request, remove any previously undisclosed 
confidential information before disclosure, except for any study- or Pfizer- intervention 
related information necessary for the appropriate scientific presentation or understanding of 
the study results.
For all publications relating to the study, the investigator will comply with recognized ethical 
standards concerning publications and authorship, including those established by the 
International Committee of Medical Journal Editors.
The sponsor will comply with the requirements for publication of the overall study results 
covering all investigator sites. In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only in their entirety and not as 
individual site data. In this case, a coordinating investigator will be designated by mutual 
agreement.
Authorship of publications for the overall study results will be determined by mutual 
agreement and in line with International Committee of Medical Journal Editors authorship 
requirements. 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 76
If publication is addressed in the clinical study agreement, the publication policy set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor’s appropriately qualified medical personnel for the 
study is documented in the study contact list located in the CTMS system. 
To facilitate access to appropriately qualified medical personnel for study-related medical 
questions or problems, participants are provided with an ECC at the time of informed 
consent. The ECC contains, at a minimum, (a) protocol and study intervention identifiers, (b) 
participant’s study identification number, and (c) site emergency phone number active 
24 hours/day, 7 days per week, and (d) Pfizer Call Center number.
The ECC is intended to augment, not replace, the established communication pathways 
between the investigator, site staff, and study team. The ECC is to be used by healthcare 
professionals not involved in the research study only, as a means of reaching the investigator 
or site staff related to the care of a participant. The Pfizer Call Center number should only be 
used when the investigator and site staff cannot be reached. The Pfizer Call Center number is 
not intended for use by the participant directly; if a participant calls that number directly, he 
or she will be directed back to the investigator site.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 77
10.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory results may be reported on these samples as a result of 
the method of analysis or the type of analyzer used by the clinical laboratory, or as derived 
from calculated values. These additional tests would not require additional collection of 
blood. Unscheduled clinical laboratory measurements may be obtained at any time during the 
study to assess any perceived safety issues.
Table 2.
Protocol-Required Safety Laboratory Assessments
Hematology
Chemistry
Urinalysis
Other
Hemoglobin
Hematocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)
BUN/urea and creatinine
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO2 (bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
Creatine kinase
Uric acid
Albumin
Total protein
Local Dipstick:
pH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Laboratory:
Microscopy and 
culturea 
•
SARS-CoV-2 RT-PCR
•
TSH
•
Free T4
•
Urine drug screeningb
•
Pregnancy test (β-hCG)c
•
aPTT
•
PT-INR
•
Fibrinogen
At screening only
•
FSHd
•
HIV
•
HBsAg
•
HBcAb
•
HCVAb 
•
HBsAbe
a.
Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase and culture only if 
bacteriuria.
b.
At screening and Day -1; The minimum requirement for drug screening includes cocaine, THC, 
opiates/opioids, benzodiazepines, and amphetamines (others are site and study specific).
c.
Local urine testing will be standard for the protocol unless serum testing is required by local regulation 
or IRB/EC. Serum or urine β-hCG for female participants of childbearing potential. 
d.
For confirmation of postmenopausal status only.
e.
HBsAb will be performed as reflex testing for any participant who is HBsAg and HBcAb positive.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF.
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and 
stored for the duration of the study.
 
 Samples to be used for this 
purpose will be shipped to either a Pfizer-approved BBS facility or other designated 
laboratory and retained for up to 1 year following the completion of the study.
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 78
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
10.3.1. Definition of AE
AE Definition

An AE is any untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or 
not considered related to the study intervention.

Note: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of study intervention.
Events Meeting the AE Definition

Any abnormal laboratory test results (hematology, clinical chemistry, or 
urinalysis) or other safety assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator. Any 
abnormal laboratory test results that meet any of the conditions below must be 
recorded as an AE:

Is associated with accompanying symptoms;

Requires additional diagnostic testing or medical/surgical intervention;

Leads to a change in study dosing (outside of any protocol-specified dose 
adjustments) or discontinuation from the study, significant additional 
concomitant drug treatment, or other therapy.

Exacerbation of a chronic or intermittent preexisting condition, including either 
an increase in frequency and/or intensity of the condition.

New condition detected or diagnosed after study intervention administration, 
even though it may have been present before the start of the study.

Signs, symptoms, or the clinical sequelae of a suspected drug–drug interaction.

Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self–harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 79
Events NOT Meeting the AE Definition

Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.

The disease/disorder being studied or expected progression, signs, or symptoms 
of the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.

Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.

Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).

Anticipated day-to-day–fluctuations of preexisting disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
An SAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a. Results in death
b. Is life-threatening-
The term “life-threatening” in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event that hypothetically might have caused death if it were more severe.
c.
Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been admitted (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting. Complications that occur during hospitalization are AEs. 
If a complication prolongs hospitalization or fulfills any other serious criteria, the 
event is serious. When in doubt as to whether “hospitalization” occurred or was 
necessary, the AE should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 80
d. Results in persistent or significant disability/incapacity

The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.

This definition is not intended to include experiences of relatively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), that may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.
e.
Is a congenital anomaly/birth defect
f.
Is a suspected transmission via a Pfizer product of an infectious agent, 
pathogenic or non-pathogenic, is considered serious. 
The event may be suspected from clinical symptoms or laboratory findings 
indicating an infection in a participant exposed to a Pfizer product. The terms 
“suspected transmission” and “transmission” are considered synonymous. These 
cases are considered unexpected and handled as serious expedited cases by 
pharmacovigilance personnel. Such cases are also considered for reporting as 
product defects, if appropriate.
g. Other situations:

Medical or scientific judgment should be exercised by the investigator in 
deciding whether SAE reporting is appropriate in other situations, such as 
significant medical events that may jeopardize the participant or may require 
medical or surgical intervention to prevent one of the other outcomes listed in the 
above definition. These events should usually be considered serious.

Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency or drug abuse.
10.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs During the Active 
Collection Period
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to Pfizer Safety throughout the active 
collection period. These requirements are delineated for 3 types of events: (1) SAEs; (2) 
nonserious AEs; and (3) exposure to the study intervention under study during 
pregnancy or breastfeeding, and occupational exposure. 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 81
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must 
be completed in a consistent manner. AEs should be recorded using concise medical 
terminology and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event
Recorded on the CRF
Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours 
of Awareness
SAE
All
All
Nonserious AE
All
None
Exposure to the study 
intervention under study 
during pregnancy or 
breastfeeding
All AEs/SAEs associated 
with exposure during 
pregnancy or breastfeeding
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.
All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE).**
Environmental or 
occupational exposure 
to the product under 
study to a non-
participant (not 
involving EDP or EDB).
None. Exposure to a study 
non-participant is not 
collected on the CRF.
The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported.***
*
EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
Pfizer Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to Pfizer Safety using the CT SAE Report 
Form. 
** 
EDB is reported to Pfizer Safety using the CT SAE Report Form which would also include 
details of any SAE that might be associated with the EDB. 
***
Environmental or Occupational exposure: AEs or SAEs associated with occupational 
exposure are reported to Pfizer Safety using the CT SAE Report Form.

When an AE or SAE occurs, it is the responsibility of the investigator to review 
all documentation (eg, hospital progress notes, laboratory reports, and diagnostic 
reports) related to the event.

The investigator will then record all relevant AE or SAE information in the CRF.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 82

It is not acceptable for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety in lieu of completion of the CT SAE Report 
Form/AE or SAE CRF page.

There may be instances when copies of medical records for certain cases are 
requested by Pfizer Safety. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records before submission to Pfizer Safety.

The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/symptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to 1 of the following categories: 

Mild: Asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.

Moderate: Minimal, local or noninvasive intervention indicated; limiting age-
appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shopping for groceries or clothes, using the telephone, managing money, etc.

Severe: Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling, limiting 
self care ADL. Self care ADL refers to bathing, dressing and undressing, feeding 
self, using the toilet, taking medications, and not bedridden.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality

The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.

A “reasonable possibility” of a relationship conveys that there are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 83

Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administration, will be considered and investigated.

The investigator will also consult the IB and/or product information, for 
marketed products, in his/her assessment.

For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality.

There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the 
sponsor.

The investigator may change his/her opinion of causality in light of follow-
up- information and send an SAE follow-up- report with the updated causality 
assessment.

The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.

If the investigator does not know whether or not the study intervention caused the 
event, then the event will be handled as “related to study intervention” for 
reporting purposes, as defined by the sponsor. In addition, if the investigator 
determines that an SAE is associated with study procedures, the investigator 
must record this causal relationship in the source documents and CRF, and report 
such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
Follow-up of AEs and SAEs

The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations, as medically indicated or as 
requested by the sponsor, to elucidate the nature and/or causality of the AE or 
SAE as fully as possible. This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other 
healthcare providers.

If a participant dies during participation in the study or during a recognized 
follow-up- period, the investigator will provide Pfizer Safety with a copy of any 
postmortem findings, including histopathology.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 84

New or updated information will be recorded in the originally submitted 
documents.

The investigator will submit any updated SAE data to the sponsor within 
24 hours of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool

The primary mechanism for reporting an SAE to Pfizer Safety will be the 
electronic data collection tool.

If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) to report the event within 24 hours.

The site will enter the SAE data into the electronic system as soon as the data 
become available.

After the study is completed at a given site, the electronic data collection tool 
will be taken off-line to prevent the entry of new data or changes to existing data.

If a site receives a report of a new SAE from a study participant or receives 
updated data on a previously reported SAE after the electronic data collection 
tool has been taken off-line, then the site can report this information on a paper 
SAE form (see next section) or to Pfizer Safety by telephone.
SAE Reporting to Pfizer Safety via CT SAE Report Form

Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety.

In circumstances when the facsimile is not working, notification by telephone is 
acceptable with a copy of the CT SAE Report Form sent by overnight mail or 
courier service.

Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated 
reporting time frames.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 85
10.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they agree to the following requirements during 
the intervention period and for at least 28 days after the last dose of study intervention, which
corresponds to the time needed to eliminate reproductive safety risk of the study 
intervention(s):

Refrain from donating sperm.
PLUS either:

Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifestyle (abstinent on a long term- and persistent basis) and 
agree to remain abstinent. 
OR

Must agree to use contraception/barrier as detailed below:

Agree to use a male condom and should also be advised of the benefit for a 
female partner to use a highly effective method of contraception as a condom may 
break or leak when having sexual intercourse with a woman of childbearing 
potential who is not currently pregnant.

In addition to male condom use, a highly effective method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly 
effective methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:

Is not a WOCBP (see definitions below in Section 10.4.3).
OR

Is a WOCBP and using a contraceptive method that is highly effective (with a failure 
rate of <1% per year), preferably with low user dependency, as described below 
during the intervention period and for at least 28 days after the last dose of study 
intervention, which corresponds to the time needed to eliminate any reproductive 
safety risk of the study intervention(s). The investigator should evaluate the 
effectiveness of the contraceptive method in relationship to the first dose of study 
intervention.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 86
A WOCBP agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during 
this period. The investigator should evaluate the effectiveness of the contraceptive method in 
relationship to the first dose of study intervention.
The investigator is responsible for review of medical history, menstrual history, and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetected 
pregnancy. 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below).
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before the first dose of study intervention, additional evaluation should be
considered.
Women in the following categories are not considered WOCBP:
1. Premenopausal female with 1 of the following: 

Documented hysterectomy;

Documented bilateral salpingectomy;

Documented bilateral oophorectomy.
For individuals with permanent infertility due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion 
should be applied to determining study entry.
Note: Documentation for any of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history interview. The method of documentation should be recorded in the 
participant’s medical record for the study.
2. Postmenopausal female.

A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition:

A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 

A female on HRT and whose menopausal status is in doubt will be required to 
use one of the non-estrogen hormonal highly effective contraception methods 

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 87
if they wish to continue their HRT during the study. Otherwise, they must 
discontinue HRT to allow confirmation of postmenopausal status before study 
enrollment. 
10.4.4. Contraception Methods
Contraceptive use by men or women should be consistent with local availability/regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependency 
1. Implantable progestogen-only hormone contraception associated with inhibition of 
ovulation.
2. Intrauterine device.
3. Intrauterine hormone-releasing system.
4. Bilateral tubal occlusion (eg, bilateral tubal ligation).
5. Vasectomized partner.

A vasectomized partner is a highly effective contraceptive method provided that 
the partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highly effective method of contraception 
should be used. The spermatogenesis cycle is approximately 90 days.
Highly Effective Methods That Are User Dependent 
6. Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation.

Oral;

Intravaginal;

Transdermal;
7. Progestogen-only hormone contraception associated with inhibition of ovulation.

Oral;

Injectable.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 88
8. Sexual abstinence.

Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study intervention. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual 
lifestyle of the participant.
One of the following effective barrier methods must be used in addition to the highly 
effective methods listed above that are user dependent:

Male or female condom with or without spermicide;

Cervical cap, diaphragm, or sponge with spermicide;

A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double-barrier methods).

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 89
 
 
 
 
 
 
 
 
 
 
 
CCI

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 90
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments
Potential Cases of Drug Induced- Liver Injury
Humans exposed to a drug who show no sign of liver injury (as determined by elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
“susceptible” to progressive and serious liver injury, commonly referred to as DILI. 
Participants who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently to determine if they are “adaptors” or are “susceptible.”
In the majority of DILI cases, elevations in AST and/or ALT precede Tbili elevations 
(>2 × ULN) by several days or weeks. The increase in Tbili typically occurs while AST/ALT 
is/are still elevated above 3 × ULN (ie, AST/ALT and Tbili values will be elevated within the 
same laboratory sample). In rare instances, by the time Tbili elevations are detected, 
AST/ALT values might have decreased. This occurrence is still regarded as a potential DILI. 
Therefore, abnormal elevations in either AST OR ALT in addition to Tbili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy’s law criteria) cases 
and should always be considered important medical events, even before all other possible 
causes of liver injury have been excluded.
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions. Participants who present 
with the following laboratory abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:

Participants with AST/ALT and Tbili baseline values within the normal range who 
subsequently present with AST OR ALT values >3 × ULN AND a Tbili value 
>2 × ULN with no evidence of hemolysis and an alkaline phosphatase value 
<2 × ULN or not available.

For participants with baseline AST OR ALT OR Tbili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:

Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is 
smaller).

Preexisting values of Tbili above the normal range: Tbili level increased from 
baseline value by an amount of at least 1 × ULN or if the value reaches 
>3 × ULN (whichever is smaller).

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 91
Rises in AST/ALT and Tbili separated by more than a few weeks should be assessed 
individually based on clinical judgment; any case where uncertainty remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferably within 48 hours from awareness of the abnormal results. This evaluation should 
include laboratory tests, detailed history, and physical assessment. 
In addition to repeating measurements of AST and ALT and Tbili for suspected Hy’s law 
cases, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analyses at the time of the recognized initial 
abnormalities to determine etiology. A detailed history, including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by itself or as a coformulated 
product in prescription or over-the-counter–medications), recreational drug, or supplement 
(herbal) use and consumption, family history, sexual history, travel history, history of contact 
with a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection, liver imaging (eg, biliary tract), and collection of serum 
samples for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and 
Tbili elevation defined above should be considered potential DILI (Hy’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable investigations have been received and have excluded an alternative etiology.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 92
10.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as AEs

Marked sinus bradycardia (rate <40 bpm) lasting minutes.

New PR interval prolongation >280 msec.

New prolongation of QTcF to >480 msec (absolute) or by ≥60 msec from 
baseline.

New onset- atrial flutter or fibrillation, with controlled ventricular response rate:
ie, rate <120 bpm.

New onset- type I second-degree- (Wenckebach) AV block of >30 seconds’ 
duration.

Frequent PVCs, triplets, or short intervals (<30 seconds) of consecutive 
ventricular complexes.
ECG Findings That May Qualify as SAEs

QTcF prolongation >500 msec.

New ST-T changes suggestive of myocardial ischemia.

New onset- left bundle branch block (QRS >120 msec).

New onset- right bundle branch block (QRS >120 msec).

Symptomatic bradycardia. 

Asystole:

In awake, symptom free- participants in sinus rhythm, with documented 
periods of asystole ≥3.0 seconds or any escape rate <40 bpm, or with an 
escape rhythm that is below the AV node. 

In awake, symptom free- participants with atrial fibrillation and bradycardia 
with 1 or more pauses of at least 5 seconds or longer. 

Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.

Sustained supraventricular tachycardia (rate >120 bpm) (“sustained” = short 
duration with relevant symptoms or lasting >1 minute).

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 93

Ventricular rhythms >30 seconds’ duration, including idioventricular rhythm 
(heart rate <40 bpm), accelerated idioventricular rhythm (HR >40 bpm to 
<100 bpm), and monomorphic/polymorphic ventricular tachycardia (HR 
>100 bpm (such as torsades de pointes)).

Type II second-degree- (Mobitz II) AV block.

Complete (third-degree-) heart block.
ECG Findings That Qualify as SAEs

Change in pattern suggestive of new myocardial infarction. 

Sustained ventricular tachyarrhythmias (>30 seconds’ duration).

Second- or third-degree- AV block requiring pacemaker placement.

Asystolic pauses requiring pacemaker placement.

Atrial flutter or fibrillation with rapid ventricular response requiring 
cardioversion.

Ventricular fibrillation/flutter.

At the discretion of the investigator, any arrhythmia classified as an adverse 
experience.
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and Pfizer study team, and not to be 
considered as all-inclusive of what to be reported as AEs/SAEs.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 94
10.8. Appendix 8: Prohibited and Precautionary Concomitant Medications That May 
Result in DDI 
The prohibited concomitant medications listed below should not be taken with PF-07321332, 
ritonavir or dabigatran during dosing and up to 4 days after the final dose of ritonavir. 
The Pfizer study team is to be notified of any prohibited medications taken during the study. 
This list of drugs prohibited or precautionary for potential DDI concerns with the IMP may 
be revised during the course of the study with written notification from sponsor, to include or 
exclude specific drugs or drug categories for various reasons (eg, emerging DDI results for 
the IMP, availability of new information in literature on the DDI potential of other drugs). 
This is not an all-inclusive list. Site staff should consult with the sponsor or designee with 
any questions regarding potential DDI.
Prohibited Medications
Medications that are Strong Inducers of CYP3A4a
Drug Class
Specific Medication
Clinical Comments
Anticoagulant
Dabigatran
Potential to impact the PK of 
PF-07321332 and ritonavir
Anti-epileptic
Phenytoin, carbamazepine
Herbal Products
St. John's wort
Medications Dependent on CYP3A4 for Clearance, with Drug Interactions with
PF-07321332/ritonavira
Alpha 1-Adrenoreceptor 
Antagonist
Alfuzosin
Risk of hypotension, syncope
Antianginal
Ranolazine
Risk of cardiac arrhythmias 
Antiarrhythmics 
Amiodarone, Bepridil, Flecainide, 
Propafenone, Quinidine, 
Dronedarone, Encainide
Risk of cardiac arrhythmias 
Antihistamines
Astemizole, Terfenadine
Risk of cardiac arrhythmias
Ergot Derivatives
Dihydroergotamine, Ergonovine, 
Ergotamine, Methylergonovine
Risk of acute ergot toxicity 
(peripheral vasospasm and ischemia 
of the extremities)
HMG CoA Reductase 
Inhibitors 
Lovastatin, Simvastatin 
Risk of rhabdomyolysis; consider 
alternative agent: pravastatin
Neuroleptic
Pimozide
Risk of cardiac arrhythmias 
PDE-5 inhibitors
Sildenafil (Revatio) - PAH
Risk of visual disturbances, 
hypotension, prolonged erection, and 
syncope
Sedatives/hypnotics
Oral Midazolam, Triazolam
Risk of prolonged sedation or 
respiratory depression
a.
If a drug is not listed, it should not automatically be assumed it is safe to co-administer.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 95
Precautionary Medications
Medications to be Used with Caution when Co-administered with PF-07321332/ritonavira
Drug Class 
Specific Drugs 
Clinical Comments 
Anticonvulsants
Lamotrigine, 
Valproate
Phenytoin
Carbamazepine
Coadministration may decrease 
lamotrigine, valproate, and phenytoin 
concentrations. 
Coadministration may increase 
carbamazepine concentrations. Careful 
monitoring of adverse effects.
Alternative agents: Gabapentin 
Topiramate
Anticoagulants
Rivaroxaban
Increased risk of bleeding, subject should 
not be enrolled if on blood thinners.
Antidepressant
Trazadone, Desipramine, Fluoxetine 
Paroxetine, Sertraline
May increase antidepressant 
concentration.
Anti-infective
Erythromycin
Coadministration may increase 
erythromycin concentration. 
Antifungals
Itraconazole
Voriconazole
Coadministration may increase 
itraconazole concentration. Monitor for 
adverse effects.
Coadministration may decrease 
voriconazole concentration.
Calcium Channel 
Blockers 
Diltiazem, Verapamil, Felodipine, 
Nicardipine, Nisoldipine, Amlodipine
Coadministration may increase 
concentrations. The impact on the PR 
interval of co-administration of ritonavir 
with other drugs that prolong the PR 
interval (including calcium channel 
blockers) has not been evaluated. If 
coadministration is indicated, consider a 
dose reduction (amlodipine
recommended dose reduction of 50%). 
Close monitoring is recommended.
Cardiac Glycosides
Digoxin
Coadministration increases digoxin 
concentration.
Hepatitis C direct 
acting antivirals
Boceprevir, Glecaprevir/Pibrentasvir
Simeprevir, 
Sofosbuvir/Velpatasvir/Voxilaprevir
Ombitasvir/Paritaprevir/Ritonavir, 
Dasabuvir
Coadministration is not recommended as 
it resulted in increased plasma 
concentrations of Hep C antiviral; 
Caution or not recommended.
HIV Protease 
Inhibitors
NNRTs, Fusion 
Inhibitors
Lopinavir, Amprenavir, Indinavir, 
Nelfinavir, Saquinavir
Abacavir, Didanosine, Zidovudine
Coadministration may increase HIV 
protease inhibitor concentrations; 
coadministration with caution.
HMG CoA reductase 
inhibitors
Atorvastatin, Rosuvastatin
Use with caution; risk of myopathy 
including rhabdomyolysis. Use lowest 
dose of statin.
Alternative agents: Pravastatin.

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 96
Precautionary Medications
Hypoglycemics
Glipizide, Tolbutamide
Repaglinide
Potentially decrease glipizide and 
tolbutamide concentrations. 
Potentially increase repaglinide 
concentrations. 
Immunosuppressants
Cyclosporine, Tacrolimus, Sirolimus
Coadministration may increase 
immunosuppressant concentrations. 
Narcotic Analgesics
Methadone, Fentanyl
Moderate to weak decreases in 
methadone AUC have been observed
Fentanyl concentration may increase.
a.
If a drug is not listed, it should not automatically be assumed it is safe to co-administer.
Prohibited Medications
Medications that are Strong Inducers of P-gp
Drug Class
Specific Medication
Clinical Comments
Antibiotic
Rifampin
Reduction to exposure of dabigatran
Medications that are Strong inhibitors of P-gp  
Antiarrhythmics
amiodarone
Increase exposures of dabigatran
Alpha/Beta Blocker
carvedilol
Increase exposures of dabigatran
Antibiotic
clarithromycin
Increase exposures of dabigatran
Calcium Channel Blocker
verapamil
Increase exposures of dabigatran
Protease Inhibitor
ritonavir
Increase exposures of dabigatran
Antifungal
itraconazole
Increase exposures of dabigatran

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 97
10.9. Appendix 9: Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbreviation
Term

ongoing/continuous event
%CI
confidence interval (%)
3CL
3C-like
3CLpro
3C-like protein
Ab
antibody
Abs
absolute
ADL
activities of daily living
AE
adverse event
AESI
adverse event of special interest
ALT
alanine aminotransferase
aPTT
activated partial thromboplastin time
AST
aspartate aminotransferase
AUC
area under the concentration-time curve
AUCinf 
area under the plasma concentration-time curve from time 0 extrapolated to 
infinity
AUClast 
area under the plasma concentration time curve from time 0 to the time of the 
last measurable concentration
AUCtau
area under the plasma concentration-time profile from time zero to time tau (τ) 
the dosing interval, where tau=12 hours for BID dosing
AV
atrioventricular
BBS
Biospecimen Banking System
-hCG 
beta-human chorionic gonadotropin
BID
twice a day
BMI
body mass index
BP
blood pressure
bpm
beats per minute
BUN
blood urea nitrogen
Cav
average concentration during a dosing interval
CBC
complete blood count
CDISC
clinical data interchange standard consortium
CFR
Code of Federal Regulations
CIOMS
Council for International Organizations of Medical Sciences
CK
creatine kinase
CKD-EPI
Chronic Kidney Disease-Epidemiology Collaboration
CL/F
apparent clearance of drug from eg, plasma
Clast
last observed (quantifiable) plasma concentration
Cmax
maximum observed plasma concentration
CO2
carbon dioxide (bicarbonate)
COVID-19
coronavirus disease 2019
CRF
case report form
CRO
contract research organization
CRU
clinical research unit

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 98
Abbreviation
Term
CSR
Clinical Study Report
CT
clinical trial
CTMS
clinical trial management system
CYP
cytochrome P450
CYP3A
cytochrome P450 3A
CYP3A4
cytochrome P450 3A4
CYP3A5
cytochrome P450 3A5
DDI
drug-drug interaction 
DILI
drug-induced liver injury
DMC
Data Monitoring Committee
EC
ethics committee
ECC
Emergency Contact Card
ECG
electrocardiogram
eCRF
electronic case report form
EDB
exposure during breastfeeding
EDP
exposure during pregnancy
eGFR
estimated glomerular filtration rate
EMA
European Medicines Agency
EOT
end of treatment
EU
European Union
EudraCT
European Clinical Trials Database
FIH
first-in-human
fm
fraction metabolized
FSH
follicle stimulating hormone
GCP
Good Clinical Practice
GGT
gamma-glutamyl transferase
GLP
Good Laboratory Practice
HBcAb
hepatitis B core antibody
HBsAb
hepatitis B surface antibody
HBsAg
hepatitis B surface antigen
HcoV
human coronavirus 
HcoV-229E
human coronavirus 229E
HcoV-HKU1
human coronavirus HKU1
HcoV-NL63
human coronavirus NL63
HcoV-OC43
human coronavirus OC43
HCT
hematocrit
HCV
hepatitis C virus
HCVAb
hepatitis C antibody
Hep C
hepatitis C
HgB
hemoglobin
HIV
human immunodeficiency virus
HMG CoA
3-hydroxy-3-methyl-glutaryl-CoA
HR
heart rate
HRT
hormone replacement therapy
IB
Investigator’s Brochure
ICD
informed consent document

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 99
Abbreviation
Term
ICH
International Council for Harmonisation
ID
identification
IMP
investigational medicinal product
IND
Investigational New Drug 
INR
international normalized ratio
IP
investigational product
IPAL
Investigational Product Accountability Log
IQMP
Independent Qualified Medical Practitioners
IRB
Institutional Review Board
IV
intravenous
ka
absorption rate constant
kel
terminal phase rate constant calculated by a linear regression of the log-linear 
concentration-time curve.
Ki
inhibition constant
kp, uu
unbound partition coefficient
LBBB
left bundle branch block
LFT
liver function test
lnAUCinf
log-transformed AUCinf
lnCmax
log-transformed Cmax
MAD
multiple ascending dose
MCH
mean corpuscular hemoglobin
MCHC
mean corpuscular hemoglobin concentration
MCV
mean corpuscular volume
MD
multiple dose
MERS
Middle East respiratory syndrome
msec
millisecond
N/A
not applicable
NHP
non-human primate
NNRT
non-nucleoside reverse transcriptase 
NOAEL
no observed adverse effect level
PAH
pulmonary arterial hypertension
PD
pharmacodynamic(s)
PDE
phosphodiesterase
PE
physical examination
P-gp
P-glycoprotein
pH
potential of hydrogen
PI
principle investigator
PK
pharmacokinetic(s)
PR
pulse rate
PT
prothrombin time
PT-INR
prothrombin time-international normalized ratio
PVC
premature ventricular contraction/complex
q12h
every 12 hours
QT
time from the beginning of the QRS complex to the end of the T wave
QTc
corrected QT interval
QTcF
corrected QT (Fridericia method)

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 100
Abbreviation
Term
qual
qualitative
QTL
quality tolerance limits
RBC
red blood cell
RR
respiratory rate
RT-PCR
reverse-transcriptase polymerase chain reaction
SAD
single ascending dose
SAE
serious adverse event
SAP
Statistical Analysis Plan
SARS-CoV-1
severe acute respiratory syndrome coronavirus 2
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
SCr
serum creatinine
SD
single dose
SoA
schedule of activities
SOP
standard operating procedure
SRSD
single-reference safety document
SUSAR
suspected unexpected serious adverse reaction
T1
Treatment 1
t½
terminal half-life
T2
Treatment 2
T3
Treatment 3
T4
thyroxine
Tbili
total bilirubin
TEAE
treatment emergent adverse event
THC
tetrahydrocannabinol
Tmax
time to first occurrence of Cmax
TSH
thyroid stimulating hormone
UGT
uridine 5’-diphospho-glucuronosyltransferase
ULN
upper limit of normal
US
United States
USPI
United States Prescribing Information
Vz/F
apparent volume of distribution
WBC
white blood cell
WHO
World Health Organization
WOCBP
woman/women of childbearing potential

PF-07321332
Protocol C4671012
Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 101
11. REFERENCES
1
Hsu A, Granneman G, Bertz R. Ritonavir: Clinical pharmacokinetics and interactions 
with other anti-HIV agents. Clin Pharmacokinet. 1998;35(4):275-91.
2
Kumar P, Gordon LA, Brooks KM, et al. Differential influence of the antiretroviral 
pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-glycoprotein transport 
and the pharmacokinetic/pharmacodynamic disposition of dabigatran. Antimicrob 
Agents Chemother. 2017;61(11):e01201-17. 
3
Härtter S, Koenen-Bergmann M, Sharma A, et al. Decrease in the oral bioavailability of 
dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 
2012;74(3):490-500.
4
Hartter S, Sennewald R, Nehmiz G et al. Oral bioavailability of dabigatran etexilate 
(Pradaxa) after co‑medication with verapamil in healthy subjects. Br J Clin Pharmacol.
2013; 75(4):1053-62.
5
World Health Organization. WHO Situation Report 51. 11 March 2020. Geneva, 
Switzerland: World Health Organization; 2020. Available from: 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. 
Accessed: 29 March 2020.
6
Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) 
structure: basis for design of anti-SARS drugs. Science. 2003;300(5626):1763-7.
7
Kaletra (lopinavir/ritonavir) capsules. USPI. North Chicago, IL: AbbVie Inc.; 2013 
Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021226s038lbl.pdf.
8
Pradaxa® (dabigatran etexilate) capsules. USPI. Ridgefield CT: Boehringer Ingelheim 
Pharmaceuticals, Inc.; 2021 Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022512s041lbl.pdf.
9
Praxbind® (Idarucizumab) injection. USPI. Ridgefield CT: Boehringer Ingelheim 
Pharmaceuticals, Inc.; 2015 Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf.